Journal of Clinical Oncology - McMaster Experts

publication venue for

Benefit of Whole-Pelvis Radiation for Patients With Muscle-Invasive Bladder Cancer: An Inverse Probability Treatment Weighted Analysis. 2025
A phase IIA clinical trial to evaluate a reversible Bruton's tyrosine kinase inhibitor (BTKi) HBW-3220 capsules in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). 2024
Adjunctive statistical standardization of quantitated adjuvant ER and PgR in CCTG MA.27 2024
Atezolizumab plus bevacizumab versus lenvatinib as first-line systemic therapy for treatment of hepatocellular carcinoma in a real-world population: Outcomes from the HCC CHORD database. 2024
Efficacy of post-lenvatinib treatments in patients (pts) with advanced renal cell carcinoma (aRCC) 2024
Evaluation of a summer program for minority high school students in the clinical cancer center: The Future Gen Cancer Scholars program. 2024
Incidence of venous thromboembolism in newly diagnosed glioblastoma multi-forme and associated risk factors: A retrospective chart review 2024
Mobilizing exercise recommendations for people with bone metastases: An experience-based co-design approach 2024
Practice patterns of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in real-world Canadian practice. 2024
Preclinical characterization of HBW-012-E, a novel, potent, selective, safe, and orally active KRAS G12D inhibitor with superior pharmacokinetic (PK) properties and anti-tumor efficacy 2024
Predictors of short-term death and long-term survival in advanced hepatocellular carcinoma (HCC) treated with contemporary tyrosine kinase inhibitors (TKI) or immunotherapy: A multicenter analysis from the HCC-CHORD consortium 2024
Real-world treatment practices in patients with muscle invasive bladder cancer (MIBC) treated in Alberta, Canada. 2024
Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial 2024
Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC) 2024
Applying the fragility index to randomized controlled trials evaluating total neoadjuvant therapy for rectal cancer. 2024
A phase II study of durvalumab re-treatment plus /- prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND.238A) 2023
Assessment of risk of overall and late distant recurrence by Breast Cancer Index in postmenopausal women with early-stage, HR plus breast cancer in the TEAM trial. 2023
Association between locoregional failure and NFE2L2/KEAP1/CUL3 pathway mutations in NRG/RTOG 9512: A randomized trial of hyperfractionation vs. conventional fractionation in T2N0 glottic squamous cell carcinoma (SCC). 2023
Association of socioeconomic status (SES) with use of specialist palliative care (SPC) among people who died with cancer before and during the COVID-19 pandemic. 2023
CCTG EN10: A phase II study of tailored adjuvant therapy in POLE-mutated and p53-wildtype/NSMP early-stage endometrial cancer (EC)-RAINBO BLUE and TAPER 2023
Can synthetic data accurately mimic oncology clinical trials? 2023
Detection of bladder cancer relapse after TURBT through urinary tumor DNA analysis: A prospective real-world evidence study 2023
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, Influence, CTS-5)? A TEAM Pathology substudy. 2023
Education modalities for serious illness communication training: A scoping review on the impact on clinician behavior and patient outcomes 2023
Evaluating response to interventions for vasomotor symptoms in patients with breast cancer: A patient-centered approach 2023
Incidence of second primary malignancies (SPMs) in patients with multiple myeloma (MM) receiving anti-CD38 monoclonal antibodies (mAbs): A systematic review and meta-analysis. 2023
Multisystem immune-related adverse events from dual agent immunotherapy use 2023
Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT). 2023
Patient-reported outcomes during pelvic radiation therapy: A secondary analysis on sexual function from NRG-RTOG 1203 2023
Phase I clinical study of orally-dosed HBW-3220 in patients with relapsed/refractory B-cell lymphoma 2023
Phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: The INVINCIBLE trial. 2023
Plasma arginine as a candidate predictive biomarker for response to immune checkpoint inhibition (ICI) in metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial 2023
Prognostic impact of PSA nadir (n) ≥0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative. 2023
Randomized placebo-controlled trial of intravenous vitamin C plus docetaxel in metastatic prostate cancer 2023
Real-world multicentre analysis of patients with hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (A plus B): Efficacy, esophagogastroduodenoscopy (EGD) uptake and bleeding complications 2023
Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy. 2023
Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC) 2023
Ultra-sensitive baseline-informed MRD assay to predict prognosis outcomes in patients with resectable hepatocellular carcinoma. 2023
Use of antibiotics and outcomes of patients presenting to emergency department with nonneutropenic fever and/or suspected infection 2023
Use of prophylactic and reactive feeding tubes in patients with esophageal cancer: A single-centre cohort study 2023
Canadian Cancer Trials Group HE.1: A phase III study of palliative radiotherapy for symptomatic hepatocellular carcinoma and liver metastases. 2023
Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative. 2022
LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T₁N₀ luminal A breast cancer (BC). 2022
BOLD-100-001 (TRIO039): A phase 1b dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastrointestinal solid cancers: Interim safety, tolerability, and efficacy 2022
CCTG BL13 a randomized phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer (NCT03768570) 2022
CCTG PR21: A randomized phase II study of [¹⁷⁷lu]lu-PSMA-617 verus docetaxel in patients with metastatic castration-resistant prostate cancer and PSMA-positive disease (NCT04663997) 2022
CCTG PR21: A randomized phase II study of [¹⁷⁷lu]lu-PSMA-617 verus docetaxel in patients with metastatic castration-resistant prostate cancer and PSMA-positive disease (NCT04663997). 2022
Clinical outcomes associated with azacitidine (AZA) monotherapy for treatment-naive, higher-risk myelodysplastic syndrome (HR-MDS): A systematic literature review and meta-analysis. 2022
Effects of liver metastases on efficacy of immune checkpoint blockade in treatment refractory, metastatic colorectal cancer (CRC): CCTG CO.26. 2022
Gender disparities in multiple myeloma publications. 2022
Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative. 2022
Intratumoral (IT) INT230-6 can cause tumor necrosis in vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study). 2022
Molecular landscape and actionable alterations in a genomic-guided cancer clinical trial: First analysis of the ROME trial. 2022
Nivolumab in squamous cell carcinomas of the head and neck (SCCHN): A real-world outcome study in Ontario, Canada. 2022
Overall survival of patients with chronic obstructive pulmonary disease receiving immunotherapy for non-small cell lung cancer: A population-based analysis in Ontario, Canada. 2022
Patient preferences for treatment and outcomes in hormone-sensitive prostate cancer (HSPC). 2022
Patient preferences for treatment and outcomes in hormone-sensitive prostate cancer (HSPC). 2022
Preliminary efficacy of optimal pharmacotherapy and patient views in multiple myeloma. 2022
Quality of end-of-life care for patients with multiple myeloma: A 12-year analysis of a population-based cohort. 2022
Quality of end-of-life care for patients with multiple myeloma: A 12-year analysis of a population-based cohort. 2022
Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notch^mut). 2022
SALVO: Single-arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma. 2022
Sentinel lymph node biopsy in Merkel cell carcinoma: A multi-institutional study from the Pan-Canadian Merkel Cell Collaborative. 2022
The RADIO trial: Randomized assessment of cisplatin dosing interval for ototoxicity with curative concurrent chemo-radiation for locally advanced head and neck squamous cell carcinoma 2022
The RADIO trial: Randomized assessment of cisplatin dosing interval for ototoxicity with curative concurrent chemo-radiation for locally advanced head and neck squamous cell carcinoma. 2022
Treatment outcomes for newly diagnosed, untreated TP53-mutated acute myeloid leukemia: A systematic review and meta-analysis. 2022
Will COVID-19 directives to reduce regularly scheduled physical examinations affect recurrence detection in patients with early breast cancer? 2022
A prospective randomized parallel-controlled pilot trial of stereotactic body radiation therapy versus radiofrequency ablation for the management of small renal masses. 2022
Association of cabozantinib dose reductions for toxicity with clinical effectiveness in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis). 2022
Contemporary outcomes of a systematic prostate cancer active surveillance program: Results from the Niagara Health System, Ontario, Canada. 2022
Development and clinical application of PredicineBEACON next-generation minimal residual disease assay for genitourinary cancers. 2022
Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC). 2022
Evolving real-world patterns of practice in metastatic castration-sensitive prostate cancer (mCSPC): The genitourinary research consortium (GURC) national multicenter cohort study. 2022
Impact of angiotensin-converting enzyme inhibitors (ACEi) on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC). 2022
Impact of lymph node yield at prostatectomy on outcomes in NRG/RTOG 9601. 2022
Longitudinal personalized urinary tumor DNA analysis in muscle-invasive bladder cancer from the neoadjuvant immunotherapy trial RJBLC-I2N003. 2022
Patterns of care for patients with non-metastatic castration-resistant prostate cancer: Population-based study in Ontario, Canada. 2022
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). 2022
Real-world management of metastatic castration-resistant prostate cancer (mCRPC): A national multicenter cohort study. 2022
Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126. 2022
Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma. 2022
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK) 2022
Nemvaleukin alfa combination therapy for gastrointestinal (GI) cancers: Preclinical evidence and clinical data from the ARTISTRY-1 trial. 2022
Perioperative optimization with nutritional supplements in patients undergoing gastrointestinal surgery for cancer: A randomized, placebo controlled feasibility clinical trial. 2022
Feasibility of a child life specialist program for oncology patients with minor children at home: Demand and implementation. 2021
Feasibility of a child life specialist program for oncology patients with minor children at home: Qualitative analysis. 2021
Myocardial injury after gynecologic oncology surgery in septuagenarians and octogenarians: Is there a role for routine postoperative cardiac biomarker monitoring? 2021
Technology interventions to support adherence to oral oncolytic agents: A systematic review and meta-analysis. 2021
Discovery of HBW-3-10: A potent, orally active, reversible Bruton's tyrosine kinase (BTK) inhibitor with antitumor activity in mice. 2021
Discovery of HBW-3-20, the first potent reversible inhibitor of Bruton's tyrosine kinase (BTK) with high brain exposure. 2021
Does early palliative care reduce end-of-life hospital costs? A propensity-score matched, population-based, cohort study. 2021
EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma. 2021
Fostering interspeciality learning in cancer survivorship care: Learning suite results. 2021
Health-related quality of life in the treatment and survivorship phases of breast cancer. 2021
ICES (International Carboplatin Emesis Survey) for the evaluation of the emetogenicity of continuous cycles of carboplatin-based chemotherapy with focus on nausea: A MASCC emesis study group, prospective, observational, real-world multi-centric study. 2021
Impact of patient, tumour and treatment factors on psychosocial outcomes in invasive breast cancer. 2021
PSMA-PET/CT Registry for Recurrent Prostate Cancer (PREP): Initial findings from a single center. 2021
Recurrent disease in patients with stage III melanoma in the era of adjuvant immune and targeted therapy. 2021
Role of adjuvant therapy in esophageal cancer patients after neoadjuvant therapy and curative esophagectomy: A systematic review and meta-analysis. 2021
Should we routinely screen for frailty prior to gynecologic oncology surgery? Frailty as a potential predictor of adverse postoperative outcomes in elderly patients. 2021
The PROVIEW+ tool: Developing and validating a tool to predict risk of poor performance status and severe symptoms in cancer patients over time. 2021
Treatment dependent improvements in survival of stage 2/3 rectal cancer patients treated with trimodality therapy between 2006-2016, an NCDB analysis. 2021
An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Final analysis for fixed-dose durvalumab monotherapy (module A). 2021
Circulating tumor DNA analysis of genomic alterations in metastatic urothelial carcinoma from NCT03113266 study. 2021
Clinical outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving radium-223 (Ra-223) early versus late in the treatment sequence. 2021
Effectiveness of first-line immune checkpoint inhibitors (ICI) in advanced non-clear cell renal cell carcinoma (ccRCC). 2021
Geographic variation in systemic therapy in men age 66 years and older with de novo metastatic castration-sensitive prostate cancer: A population-based study in a single payer health-system. 2021
Impact of angiotensin blockade on response to PD1/L1 inhibitors for patients with metastatic urothelial carcinoma (mUC). 2021
Impact of angiotensin inhibitors on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC). 2021
Longitudinal predictive ability of mapping algorithms: Secondary analysis of NRG Oncology/RTOG 0415. 2021
Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study. 2021
Prognostic association between common laboratory tests and overall survival in men with de novo metastatic castration-sensitive prostate cancer: A population-based study. 2021
Real-world utilization of docetaxel among men with de novo metastatic castration-sensitive prostate cancer: A population-based study in men aged 66 or older. 2021
Superior molecular pathology of urothelial bladder cancer using urinary cell-free DNA. 2021
BOLD-100-001 (TRIO039): A phase Ib dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastrointestinal solid tumors. 2021
Changes in treatment and outcomes of stage II/III rectal cancer patients treated with trimodality therapy (TT) between 2006-2016: An NCDB analysis. 2021
Treatment patterns and survival outcomes of older patients with advanced pancreatic cancer (APC): A Canadian real-world evidence study. 2021
Assessing burnout among oncologists in Ontario, Canada. 2020
Comparing characteristics and outcomes of cancer to non-cancer patients admitted to general internal medicine (GIM). 2020
Fostering interspeciality learning in cancer survivorship care: Learning suite results. 2020
A multicenter study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of taxotere/cyclophosphamide-induced febrile neutropenia in patients with early-stage breast cancer. 2020
A phase II multicenter study of stereotactic radiotherapy (SRT) for oligoprogression in metastatic renal cell cancer (mRCC) patients receiving tyrosine kinase inhibitor (TKI) therapy. 2020
Cell-free DNA comparative analysis of hormone receptor-positive, first-line metastatic breast cancer genomic landscape in the United States and China. 2020
Clinical outcomes of pancreas cancer patients with peritoneal spread: Results from the chord consortium. 2020
Cost-effectiveness of nodal observation versus completion lymphadenectomy in patients with melanoma and sentinel lymph node metastases. 2020
Demonstrating the value of liquid biopsy for lung cancer in a public health care system. 2020
Demonstrating the value of liquid biopsy for lung cancer in a public health care system. 2020
Development and validation of a risk prediction model for poor performance status and severe symptoms among cancer patients. 2020
Dissecting outcomes of patients (pts) with < ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration. 2020
Early discontinuation to adjuvant endocrine therapy in the ECOG-ACRIN TAILORx Trial. 2020
Effect of neoadjuvant immunotherapy and targeted therapies on surgical resection in patients with solid tumors: A systematic review and meta-analysis. 2020
FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC). 2020
FRACTION-RCC: Innovative, high-throughput assessment of nivolumab plus ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC). 2020
Impact of concurrent angiotensin inhibitors on outcomes with PD1/L1 inhibitors for patients (pts) with metastatic urothelial carcinoma (mUC). 2020
Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC). 2020
Locoregional recurrence following pathologic complete response in patients with T1-3 N0 breast cancer treated with neoadjuvant chemotherapy, breast conserving surgery and whole breast radiation: Is a trial of omission of radiation warranted? 2020
Outcomes of patients (pts) with metastatic urothelial carcinoma (mUC) following discontinuation of enfortumab-vedotin (EV): Emergence of a new unmet need. 2020
Prostate cancer biomarker enrichment and treatment selection (PC-BETS) study: A Canadian cancer trials group phase II umbrella trial for metastatic castration-resistant prostate cancer (mCRPC). 2020
Prostate cancer biomarker enrichment and treatment selection (PC-BETS) study: A Canadian cancer trials group phase II umbrella trial for metastatic castration-resistant prostate cancer (mCRPC). 2020
Psychosocial outcomes following surgery in women with unilateral, nonhereditary breast cancer. 2020
The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL). 2020
The characterization of IDH1 mutations in Chinese biliary tract cancers. 2020
The impact of primary pancreatic tumor location on clinical outcomes in advanced disease: Results from the chord consortium. 2020
The impact of tobacco retail density on overall survival (OS) in lung cancer survivors. 2020
Two-year survival with nivolumab in previously treated, advanced non-small cell lung cancer: A pooled analysis of real-world patients from France, Germany and Canada. 2020
Two-year survival with nivolumab in previously treated, advanced non-small cell lung cancer: A pooled analysis of real-world patients from France, Germany and Canada. 2020
A comparison of combined immune checkpoint inhibitors (IO) versus vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in the treatment of advanced clear cell renal cell carcinoma 2020
A methodological comparison of mapping algorithms to obtain health utilities derived using cross-sectional and longitudinal data: Secondary analysis of NRG/RTOG 0415 2020
A multicenter phase II study of avelumab in patients with locally advanced or metastatic penile cancer (PC) who are unfit for, or have progressed on or after platinum-based chemotherapy: (ALPACA) 2020
An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Interim safety results for fixed-dose durvalumab (D) monotherapy (module A) 2020
An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Interim safety results for fixed-dose durvalumab (D) monotherapy (module A). 2020
Any regression of tumor (ART) within 12 weeks versus RECIST 1.1 response category as an intermediate endpoint to assess the activity of immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC) 2020
Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC) 2020
Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). 2020
Conditional immune adverse event rate in urothelial and renal cell carcinoma patients treated with immune checkpoint inhibitors 2020
FDG and PSMA PET in metastatic castration-resistant prostate cancer (mCRPC) 2020
FDG and PSMA PET in metastatic castration-resistant prostate cancer (mCRPC). 2020
Impact of early identification of brain metastases in metastatic renal cell carcinoma (mRCC) 2020
Impact of early identification of brain metastases in metastatic renal cell carcinoma (mRCC). 2020
Impact of histology and toxicities on outcomes of patients with muscle invasive bladder cancer receiving neoadjuvant chemotherapy 2020
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK) 2020
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). 2020
Plasma cell-free DNA (cfDNA) profiling of copy number variation (CNV) to identify poor prognostic biomarkers in metastatic castration-resistant prostate cancer (mCRPC) 2020
Real-world evidence of cabozantinib in metastatic renal-cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis) 2020
Real-world management of advanced prostate cancer: A Canadian comparison of academic specialists and community-based prostate cancer physicians 2020
Real-world management of advanced prostate cancer: A Canadian comparison of academic specialists and community-based prostate cancer physicians. 2020
Real-world utilization and safety of ipilimumab plus nivolumab (I plus N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis) 2020
Real-world utilization and safety of ipilimumab plus nivolumab (I+N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis). 2020
Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC) 2020
Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). 2020
The effect of docetaxel, enzalutamide, abiraterone, and radium-223 on cognitive function in older men with metastatic castrate-resistant prostate cancer (mCRPC) 2020
The effect of docetaxel, enzalutamide, abiraterone, and radium-223 on cognitive function in older men with metastatic castrate-resistant prostate cancer (mCRPC). 2020
The prevalence of cardiovascular disease and its risk factors among prostate cancer patients treated with and without androgen deprivation 2020
Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial 2020
Real-world outcomes for metastatic non-small cell lung cancer patients treated with checkpoint inhibitor immunotherapy in Canada 2020
Real-world outcomes for metastatic non-small cell lung cancer patients treated with checkpoint inhibitor immunotherapy in Canada. 2020
Effect of neoadjuvant immunotherapy and targeted therapies on surgical resection in patients with solid tumors: A systematic review and meta-analysis 2020
Influenza Vaccine Effectiveness Among Patients With Cancer: A Population-Based Study Using Health Administrative and Laboratory Testing Data From Ontario, Canada 2019
5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors. 2019
A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies. 2019
A phase I study of [²²⁵Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors. 2019
A randomized study comparing physician-directed or fixed-dose dexamethasone replacement following incomplete steroid premedication for docetaxel chemotherapy. 2019
Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). 2019
Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs). 2019
CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC). 2019
Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and antagonist among patients with advanced prostate cancer. 2019
Cctg MA.39 tailor RT: A randomized trial of regional radiotherapy in biomarker low-risk node-positive breast cancer (NCT03488693). 2019
Cost disparities with age in the treatment of advanced non-small cell lung cancer (NSCLC) in Ontario, Canada. 2019
Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia/lymphoma: Results of DFCI 11-001. 2019
First-line PD(L)1 inhibitors for platinum-ineligible advanced urothelial carcinoma (aUC). 2019
Genomic testing and treatment landscape in patients with advanced non-small cell lung cancer (aNSCLC) using real-world data from community oncology practices. 2019
Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiotherapy (CRT) plus /- metformin in locally advanced Non-Small Cell Lung Cancer (NSCLC). 2019
Prognostic factors associated with short-term survival (STS) in advanced pancreatic cancer (APC): A Canadian multicenter analysis from the CHORD Consortium. 2019
Simultaneous versus staged resection for synchronous colorectal cancer liver metastases: A population-based cohort study. 2019
The ESCAPADE Study: Early supportive care for advanced cancer patients, assessing care delivery and provider engagement. 2019
The effect of metformin on sex hormones in non-diabetic breast cancer patients in CCTG MA.32: A Phase III randomized adjuvant trial of metformin versus placebo in addition to standard therapy. 2019
The impact of routine ESAS use on overall survival: Results of a population-based retrospective matched cohort analysis. 2019
Tobacco retail availability and tobacco cessation in lung and head and neck (HN) cancer survivors. 2019
Updated results from a randomized phase II study of cabazitaxel (CAB) versus abiraterone (ABI) or enzalutamide (ENZ) in poor prognosis metastatic CRPC. 2019
weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration resistant prostate cancer. 2019
Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis). 2019
First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC). 2019
Identification, incidence and clinical outcomes of patients (pts) with hypermutated prostate cancer (PC). 2019
Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC). 2019
Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma. 2019
Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs). 2019
Investigating a novel recombinant antibody to attenuate prostate cancer progression by targeting cell surface GRP78. 2019
Mechanisms underlying the association between sarcopenia and poor oncologic outcomes in clear cell renal cell carcinoma. 2019
Prostate cancer-derived anti-GRP78 autoantibodies compromise the blood-brain barrier and accelerate atherosclerosis progression in vivo. 2019
Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors. 2019
CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC). 2019
Prognostic factors associated with long term survival in chemotherapy-treated advanced pancreatic cancer: A Canadian multicenter analysis. 2019
Simultaneous resection of colorectal cancer with synchronous liver metastases: A survey-based analysis. 2019
Simultaneous versus staged resection for synchronous colorectal cancer liver metastases: A population-based cohort study. 2019
Oncologists and medical assistance in dying: Where do we stand? 2018
Active identification of patients appropriate for palliative care: Impact on use of palliative care and home care resources. 2018
Cancer patient (pt) attitudes and preferences towards smoking status assessment. 2018
Defining a patient-reported outcome measure (PROM) selection process: What criteria should be considered when choosing a PROM for routine symptom assessment in clinical practice? 2018
Does the risk of emergency department visits and hospitalizations during systemic therapy for cancer influence patient decisions regarding treatment? 2018
Evaluation of the implementation of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) across the province of Ontario. 2018
The impact of routine ESAS use on receiving palliative care services: Results of a population-based retrospective matched cohort analysis. 2018
Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: Efficacy and safety in the phase III randomized factorial ASPECT trial. 2018
A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP): Canadian Clinical Trials Group study (CCTG) ME.13. 2018
CA15-3/MUC1 in CCTG MA-32 (NCT01101438): A phase III RCT of the effect of metformin vs. placebo on invasive disease free and overall survival in early stage breast cancer (BC). 2018
Does the risk of emergency department visits and hospitalizations during systemic therapy for cancer influence patients’ decisions regarding treatment? 2018
Effect of PET-CT on disease recurrence and its management in patients with potentially resectable colorectal cancer liver metastases. The long-term results of a randomized controlled trial (PET-CT Imaging prior to liver resection for colorectal adenocarcinoma metastases). 2018
Evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction. 2018
Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients. 2018
Limited stage nodular lymphocyte predominant Hodgkin lymphoma (NLPHL): A subgroup analysis of the HD.6 clinical trial. 2018
Opioid use in long term cancer survivors. 2018
Preclinical studies of BMI-1 modulator PTC596 in diffuse intrinsic pontine gliomas, pediatric high-grade gliomas and medulloblastoma 2018
Prospective linkage of clinical trial and administrative databases: Acceptability to patients and research ethics boards. 2018
Timing of androgen deprivation therapy for prostate cancer patients after radiation: Planned combined analysis of two randomized phase 3 trials. 2018
Ascertaining cancer survivors in Ontario using the Ontario Cancer Registry and administrative data. 2018
Cancer patient attitudes and preferences towards smoking status assessment. 2018
Evaluating the impact of survivorship models on health system resources and costs. 2018
The impact of a well breast cancer patient transition model of care on oncologists’ practice. 2018
C-reactive protein as a prognostic factor in advanced urothelial carcinoma receiving chemotherapy or immunotherapy. 2018
CD73 expression in primary and metastatic renal cell carcinoma (RCC). 2018
Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials. 2018
Cell surface GRP78 activation by anti-GRP78 autoantibodies in relation to prostate tumour growth via tissue factor activation. 2018
Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma. 2018
Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy. 2018
New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab. 2018
Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma. 2018
Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study. 2018
Patterns of prostate cancer management across Canadian prostate cancer treatment specialists. 2018
Real world patterns of treatment sequencing in Canada for metastatic castrate-resistant prostate cancer. 2018
Renal cell carcinoma (RCC) primary tumor shrinkage on vascular endothelial growth factor (VEGF)-targeted therapy (TT): A pooled analysis. 2018
Statin use and outcomes of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) being treated with abiraterone (Abi). 2018
A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (MOBILITY-002 Trial, NCT02428270). 2018
Chemotherapy choice in advanced pancreatic cancer: What patient and disease factors influence prescription patterns? 2018
Comparative effectiveness and safety of the implementation of universal public funding of FOLFIRINOX (FFX) and gemcitabine (G) + nab-paclitaxel (GnP) in advanced pancreatic cancer (APC): A population-based study. 2018
Effect of PET-CT on disease recurrence and its management in patients with potentially resectable colorectal cancer liver metastases: The long-term results of a randomized control trial. 2018
Major arterial resection for stage 3 adenocarcinoma of the pancreas. 2018
Systematic review and meta-analysis of the effect of pre-operative PET/PET-CT in the management of patients with potentially resectable colorectal cancer liver metastasis. 2018
High-intensity Focused Ultrasound (HIFU) as salvage therapy for radio-recurrent prostate cancer: predictors of disease response. 2018
Code status communication training in Canadian postgraduate oncology programs: A needs assessment survey. 2017
The PULSES project: Teaching the vital elements of code status discussions to oncology residents. 2017
Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer: Pharmacokinetic data 2017
A meta-analysis of trials of etoposide plus platinum agent versus irinotecan/topotecan plus platinum agent in first-line therapy of extensive stage small cell lung cancer (ES SCLC). 2017
A randomized phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer (mCRPC): Canadian Cancer Trials Group study IND 209. 2017
Abiraterone +/- cabazitaxel in defining complete response in prostatectomy (ACDC-RP) trial. 2017
Association between progression-free survival and health-related quality of life in oncology: A systematic review and regression analysis. 2017
Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape. 2017
Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT). 2017
Comparison of prognostic models for hepatocellular carcinoma (HCC) in patients treated with the sorafenib: Results from a Canadian multi-center HCC database. 2017
Exploratory phase II evaluation of cabozantinib in recurrent/metastatic uterine carcinosarcoma (CS): A study of the Princess Margaret, Chicago, and California phase II consortia. 2017
Immune related adverse events (irAE) with platinum chemotherapy (CT) with durvalumab (D) ± tremelimumab (T): CCTG IND226. 2017
Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). 2017
NCI Breast Cancer Steering Committee Working Group (WG) report on meaningful and appropriate endpoints for clinical trials (CT) in metastatic breast cancer (MBC). 2017
Neurocognitive functions and psychological distress in young adults with cancer (YAC): A prospective, longitudinal study. 2017
Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012. 2017
Nomogram to assess survival benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials. 2017
Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer. 2017
Phase I study of oncolytic virus (OV) MG1 maraba/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214. 2017
Phase II study of cabozantinib (cabo) in patients (pts) with recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago, and California phase II consortia. 2017
Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer. 2017
Rates of trastuzumab-associated cardiotoxicity in patients with HER2-positive breast cancer at a tertiary cancer centre. 2017
Retrospective analysis of ipilimumab-induced diarrhea and/or colitis: A single centre review. 2017
Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide. 2017
The PULSES project: Teaching the vital elements of code status discussions to oncology residents. 2017
Use of a marketing plan for recruitment to a lung cancer screening study. 2017
A person-centered e-proms multi-faceted intervention to improve patient experience and health outcomes: A multi-site implementation study in diverse ambulatory oncology practices. 2017
An evaluation of the breast cancer Well Follow-up Care Initiative using administrative databases: A new model of analysis. 2017
Developing and evaluating new models of care in hematology. 2017
Funding model for stem cell transplant. 2017
Multidisciplinary cancer conferences as a forum for early identification of patients who can benefit from a palliative approach to care: INTEGRATE quality improvement project. 2017
Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). 2017
Prognostic classification of muscle-invasive bladder cancer (MIBC) following radical cystectomy (RC) alone or with perioperative chemotherapy: Analysis of the U.S. National Cancer Database (NCDB). 2017
Identifying critical data elements for a provincial transition plan from a primary care perspective. 2017
Understanding and improving knowledge of cancer survivorship care among college providers. 2017
Using a mobile app to enhance the uptake of survivorship care plans (SCP) for adolescent and young adult survivors of childhood cancer. 2017
Association of adjuvant chemotherapy with improved overall survival for patients with locally advanced rectal cancer (LARC) who achieve a pathologic complete response (pCR) to neoadjuvant chemoradiation (nCRT). 2017
Does the addition of biologic agents to chemotherapy in patients with unresectable colorectal cancer metastases result in a higher proportion of patients undergoing resection? A systematic review and meta-analysis. 2017
Incidence of venous thromboembolic events following major pelvic and abdominal surgery for cancer. 2017
Outcomes of FOLFIRINOX (FFX) and gemcitabine+nab-paclitaxel (GnP) in initially unresectable locally advanced pancreatic cancer (uLAPC): A population-based study. 2017
Topographical incidence and survival analysis of gastrointestinal tract cancer in adolescent and young adults compared with older adults in the United States. 2017
Efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gastrointestinal and colorectal cancers. 2016
A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). 2016
A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. 2016
Patient-reported outcomes from MA.17R: A randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. 2016
A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. 2016
Anthracycline-induced cardiotoxicity in patients with early stage breast cancer: The Canadian cancer trials group (NCIC CTG) MA.21 experience. 2016
Anti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC). 2016
CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. 2016
Comparing cervical cancer stage at diagnosis in immigrant women and long-term residents. 2016
Cytoreductive surgery (CRS) and heated intra-peritoneal chemotherapy (HIPEC) in the management of peritoneal carcinomatosis in a community setting. 2016
Developing and evaluating new models of care in hematology. 2016
Do women who self-report cognitive symptoms after breast cancer treatment have more cognitive impairment than those who do not report symptoms? A mechanistic cohort study with functional brain MRI. 2016
Dynamic angiogenic switch as predictor of response to chemotherapy+ bevacizumab in patients with metastatic colorectal cancer. 2016
Effects of a structured exercise program on physical activity and health-related fitness in colon cancer survivors: One year feasibility results from the NCIC CTG CO.21 (CHALLENGE) trial. 2016
Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study. 2016
Impact of the 21-gene Recurrence Score assay on the adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes in an academic centre in Ontario. 2016
KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy. 2016
Multi-site implementation of patient-reported outcome measures for personalized care and patient activation in symptom management. 2016
Phase I pharmacokinetic study of single agent trametinib in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study. 2016
Phase II study of cabozantinib in recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago and California Phase II Consortia. 2016
Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR). 2016
Pre-screening test for clinical trials of Autologous γδ T lymphocyte therapy for advanced cancer. 2016
Readmission and emergency department visits in the peri-treatment period for head and neck cancers patients in Ontario. 2016
Reasons for delay in time to initiation of adjuvant chemotherapy (TTAC) for colon cancer (CC): Analysis from six academic centers in Ontario, Canada. 2016
Suggested reclassification strategy applied to intermediate and poor risk nonseminomatous germ cell tumors (NSGCT): A two-institution combined analysis. 2016
Using cognitive interviews and expert feedback to validate the Australian AYA Distress Thermometer and Problem Checklist for use in Canada. 2016
Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421. 2016
Assessing the quality of chemotherapy in an episode-based funding model in Ontario 2016
Bringing person-centered care to practice with CCO’s guideline for person-centred care in adult oncology services. 2016
Initiative to streamline clinical trials (ISCT): Guidance for academic investigators/sponsors. 2016
Optimizing the collection and reporting of wait time data. 2016
Pathway map development as an approach to identifying priority areas for quality improvement in Ontario. 2016
Recommendations for the delivery of focal tumor ablation services. 2016
Standardizing architecture and governance of radiology clinical checklist development. 2016
Time trends in opioid use in cancer and noncancer patients: Observations from administrative data. 2016
Using a disease pathway management approach to improve the quality of breast cancer care in Ontario. 2016
Effects of a structured exercise program on physical activity and health-related fitness in colon cancer survivors: One year feasibility results from the NCIC CTG CO.21 (CHALLENGE) trial. 2016
PET-CT compared to no PET-CT in the management of potentially resectable colorectal cancer liver metastases: The costs implications of a randomized controlled trial 2016
Bridging the gap: The design of a survivorship curriculum for interspecialty collaboration. 2016
Integrating primary care and cancer care in survivorship: A collaborative approach. 2016
Neurocognitive function and psychological distress in young adults (YA) with cancer. 2016
Patient-generated online survivorship care plans for adult survivors of childhood cancer: Feasibility and patient preferences. 2016
Effect of anti-GRP78 autoantibodies on prostate cancer progression through tissue factor procoagulant activity. 2016
Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC). 2016
Impact of single agent daily prednisone on survival and toxicities in post-docetaxel men with metastatic castration-resistant prostate cancer (mCRPC): An analysis of 2 phase III trials. 2016
Incidence, characteristics, and implications of thrombo-embolic events in patients with urothelial carcinoma of the bladder undergoing neoadjuvant chemotherapy. 2016
Integration of bone scan (BS) and computerized tomography (CT) findings as an endpoint to assess bone metastasis in metastatic castration-resistant prostate cancer (mCRPC). 2016
NRG Oncology RTOG 0415: A randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer. 2016
NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA. 2016
Outcomes of advanced urothelial carcinoma following discontinuation of programmed death (PD)-1 or PD-ligand (L)-1 inhibitors. 2016
Patient reported outcomes in NRG Oncology/RTOG 0938, evaluating two ultrahypofractionated regimens (UHR) for prostate cancer (CaP). 2016
The RADICAL-PC trial. 2016
Development of provincial clinical standards for the province of Ontario. 2015
Meta-analysis: Risk of congestive heart failure (CHF) in selected targeted agents. 2015
A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma. 2015
A phase I study of BI 853520, an inhibitor of focal adhesion kinase (FAK), in patients with advanced or metastatic solid tumors. 2015
A phase I/II clinical trial of veliparib (ABT-888) and radiation followed by maintenance therapy with veliparib and temozolomide in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG): A Pediatric Brain Tumor Consortium Interim Report of Phase I Study. 2015
A phase I/II study of ipilimumab in women with metastatic or recurrent cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia. 2015
A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21). 2015
A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197. 2015
A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197. 2015
A single institution experience of salvage therapy for locally advanced breast cancer: Treatments and trends. 2015
Analytical validation of StrandAdvantage solid tumor NGS test. 2015
Blood and urine markers of metabolic dysfunction in colorectal cancer: a pilot study. 2015
Can oncology readmissions be reduced? The Cleveland Clinic experience. 2015
Cancer-related cognitive dysfunction (CRCD) and psychosocial development in young adult cancer survivors. 2015
Cardiovascular events in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors: A systematic review and meta-analysis. 2015
Expression of thyroid hormone receptor alpha (THR alpha) isoforms in triple negative breast cancer (TNBC) 2015
Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC). 2015
First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. 2015
First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. 2015
Gemcitabine and platinum (GC) chemotherapy alone or with a taxane (GC-T) as first-line therapy for urothelial cancer (UC): A meta-analysis. 2015
Impact of rolapitant on quality of life (QoL) in patients (pts) receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) 2015
Improving fitness after childhood cancer: A novel exercise clinic for pediatric oncology patients. 2015
Meta-analysis of the impact of single agent daily prednisone on outcomes and toxicities in metastatic castration-resistant prostate cancer (mCRPC). 2015
NCIC CTG IND.206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers. 2015
Outcome of neurofibromatosis type 1 patients treated with first line vinblastine for optic pathway gliomas: A Canadian multicenter study. 2015
Phase 1 study with expansion cohorts of cabozantinib (C) + abiraterone (A) in metastatic castration resistant prostate cancer (mCRPC): Investigator-sponsored study. 2015
Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC). 2015
Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trial. 2015
Physicians' attitudes toward systematic symptom assessment and management: Results from all regional cancer centres in Ontario (Canada). 2015
Quality of life (QOL) in a phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 (NCT00820248). 2015
Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity. 2015
The role of PET-CT in treatment decision making for women with locally advanced cervical cancer. 2015
The role of biomarkers in improving clinical trial success: A study of 1,079 oncology drugs. 2015
Trends in demographics, incidence, and survival in children, adolescents and young adults (AYA) with melanoma: A Surveillance, Epidemiology and End Results (SEER) population-based analysis 2015
Tumor treating fields (TTFields): A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma—First report of the full dataset of the EF14 randomized phase III trial. 2015
Validation of correlation of RECIST changes with survival in metastatic castration-resistant prostate cancer (mCRPC). 2015
A randomized trial of 79.2Gy versus 70.2Gy radiation therapy (RT) for localized prostate cancer. 2015
Association of changes in measurable disease by RECIST with survival in metastatic castration-resistant prostate cancer (mCRPC). 2015
IND 205B: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone. 2015
Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy. 2015
Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma. 2015
The proportion and characterization of patients with metastatic renal cell carcinoma who are never treated or have delayed treatment with targeted therapy: Results from a large prospective cohort. 2015
Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation (TMT): An international collaboration. 2015
Identifying variables that predict poor tumor biology and suboptimal outcomes in patients treated with cytoreduction and HIPEC. 2015
Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity. 2014
A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors. 2014
A phase 1 multicenter clinical trial of alemtuzumab and CHOP chemotherapy for peripheral T-cell lymphomas. 2014
A phase 1/2 study of ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia. 2014
A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers. 2014
A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21). 2014
A randomized phase 3 trial of thalidomide and prednisone (TP) as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): An updated analysis of the NCIC Clinical Trials Group MY10 trial. 2014
A targeted intervention to improve awareness to molecular testing in NSCLC. 2014
Adjuvant radiation, androgen deprivation, and docetaxel for high-risk prostate cancer post-prostatectomy: Results of RTOG 0621. 2014
Androgen pathway manipulation and outcome in elderly men with non-small cell lung cancer: A population-based study from Ontario, Canada. 2014
Assessment of a dyspnea clinic for patients with thoracic malignancies 2014
Cancer worry, anxiety, and behaviors in girls at familial or genetic risk for breast cancer. 2014
Chemoradiation for locally advanced penile squamous cell carcinoma (PSCC): A multi-institution retrospective study. 2014
Correlation between phase 2 clinical trial design and subsequent phase 3 outcome. 2014
Do patients with small cell lung cancer (SCLC) who have chemotherapy initiated during a hospital admission benefit from therapy? 2014
Does routine symptom screening with the Edmonton Symptom Assessment System (ESAS) decrease emergency department visits in breast cancer patients undergoing adjuvant chemotherapy? 2014
Effect of continued imatinib (IM) in pts with detectable BCR-ABL after ≥ 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr. 2014
Evaluation of the adjuvant radiation treatment-effect heterogeneity using genomic signature for locoregional relapse and long-term outcome. 2014
External validation of nomogram to predict progression-free survival at 6 months (PFS6) in patients receiving salvage therapy for advanced urothelial carcinoma (UC). 2014
Final analysis of a large, open-label global early access protocol (EAP) with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy. 2014
First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. 2014
First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. 2014
Impact of health care professional interventions on completion of therapy in patients receiving high-dose interferon-alfa 2b adjuvant therapy for high-risk melanoma. 2014
Interobserver variation in predicting fracture risk in patients with long bone metastatic lesions. 2014
NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI. 2014
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. 2014
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). 2014
Outcome of childhood T-cell acute lymphoblastic leukemia (T-ALL): Results from DFCI protocol 05-001. 2014
PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)based chemotherapy (CT). 2014
Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors. 2014
Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors. 2014
Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial of the PMH, Chicago, and California Phase II Consortia. 2014
Phase II study of oral ENMD-2076 administered to patients with ovarian clear cell carcinoma: A trial of the Princess Margaret Phase II Consortium. 2014
Population-based evaluation of 21-gene assay in treatment decision making for early breast cancer in Ontario. 2014
Preoperative window-of-opportunity (WOO) study of dacomitinib (Dac) in patients (Pts) with resectable oral cavity squamous cell carcinoma (OCC): Generation of a gene expression signature (DGS) as a predictor of Dac activity. 2014
Prognostic and predictive significance of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. 2014
Prognostic associations of 25OH vitamin D in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC). 2014
Prognostic factors in hemangioendotheliomas (HE): Analysis based on the Surveillance, Epidemiology, and End Results (SEER) program. 2014
Prognostic potential of thyroid receptor TRα2 in breast cancer. 2014
Reasons for delay in time to initiation of adjuvant chemotherapy for colon cancer: A multi-institution study. 2014
Results from an interdisciplinary palliative rehabiliation program for patients living with advanced cancer. 2014
The use of health-related quality of life outcomes in oncology practice: An international study. 2014
Using Magee equations to predict Oncotype DX recurrence scores: A potential cost and time saving strategy? 2014
Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC) patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin (Met) to placebo (Pl). 2014
Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy. 2014
Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy. 2014
Pain palliation as an oncology label indication: Lessons learned in custirsen phase III development. 2014
Positive surgical margins after partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer Information System database. 2014
Prognostic impact of C-reactive protein (CRP) in metastatic prostate cancer (MPC): A systematic review and meta-analysis. 2014
Simultaneous cone beam CT scanning during prostate radiotherapy to produce clinically useful images. 2014
The role of FSH in castration-induced adipogenesis and cardiovascular diseases: Highlighting differences between orchiectomy, GNRH agonists, and antagonists. 2014
Transurethral (TURP) biopsy of suspected anterior prostate cancers identified by MRI: Pilot study of a novel technique. 2014
A case series of Lynch syndrome-associated breast cancer. 2014
Functional BRM promoter polymorphisms, pancreatic adenocarcinoma risk, and survival. 2014
Safety and antitumor activity of selinexor (KPT-330), a first-in-class, oral XPO1 selective inhibitor of nuclear export: A phase I study expanded with colon cancer cohort. 2014
Access to personalized medicine: Factors influencing the use and value of gene expression profiling in treatment decision making. 2013
Identifying knowledge-translation opportunities in the treatment of locally advanced breast cancer. 2013
A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies 2013
A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies. 2013
A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer 2013
A multicenter phase II study of bevacizumab (B) and temsirolimus (T) in women with recurrent epithelial ovarian cancer (OC): A study of the Mayo, Chicago, California, New York, Southeast, and Princess Margaret Phase II Consortia 2013
A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts) 2013
A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). 2013
A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: Final analysis. 2013
A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: Final analysis. 2013
A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer. 2013
A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer. 2013
A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21) 2013
A randomized phase II study of cediranib (CED) alone versus CED plus dasatinib (DAS) in patients (pts) with castration-resistant prostate cancer (CRPC). 2013
A randomized phase II study of cediranib (CED) alone versus CED plus dasatinib (DAS) in patients (pts) with castration-resistant prostate cancer (CRPC). 2013
A randomized trial of single versus multiple fractions (Fx) for re-irradiation (RE-RT) of painful bone metastases (PBM): NCIC CTG SC.20. 2013
Bowel obstruction with stage IV cancer: The benefit of introduction of formal palliative care service. 2013
Canadian ALK (CALK): A pan-Canadian multicenter study to optimize and standardize ALK immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for ALK gene rearrangements 2013
Cancer Care Ontario's lung disease pathway initiative: Building resources for lung cancer quality care 2013
Characteristics of clinical trials for adolescent and young adult (AYA) cancer patients (pts) in Ontario. 2013
Clinical impact of EGFR mutation fraction and tumor cellularity in EGFR mutation positive NSCLC. 2013
Cochrane systematic review and meta-analysis of adjuvant chemotherapy for stage II colon cancer 2013
Competing risks of death in NCIC CTG MA.27 adjuvant exemestane versus anastrozole. 2013
Design of the AFFINITY study: A randomized phase III study of a novel clusterin inhibitor, custirsen, plus cabazitaxel/prednisone (CbzP) versus CbzP alone as second-line chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). 2013
Design of the AFFINITY study: A randomized phase III study of a novel clusterin inhibitor, custirsen, plus cabazitaxel/prednisone (CbzP) versus CbzP alone as second-line chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). 2013
Development of a practice consensus statement of the management of locally advanced breast cancer: Expert consensus and systematic review. 2013
Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC) 2013
Effective routine electronic symptom screening and use of evidence to improve cancer symptom management in Ontario, Canada. 2013
Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial 2013
Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial. 2013
Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM) 2013
Final results of a phase I study evaluating the combination of linsitinib, a dual inhibitor of insulin-like growth factor-1 receptor (IGF-1R), and insulin receptor (IR) with weekly paclitaxel (PAC) in patients (Pts) with advanced solid tumors. 2013
First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors. 2013
Identification of knowledge translation opportunities in the treatment of locally advanced breast cancer: Results of a national survey of physicians 2013
Impact of response to prior chemotherapy (RTPC) on outcomes in second-line therapy for advanced urothelial carcinoma (UC): Implications for trial design. 2013
Impact of wait times on survival of women with uterine cancer. 2013
Interim safety results of a global early access protocol (EAP) of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after taxane-based chemotherapy 2013
Interim safety results of a global early access protocol (EAP) of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after taxane-based chemotherapy. 2013
NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC). 2013
NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC). 2013
Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC) 2013
Ovarian cancer distribution of histology, stage, and screening performance 2013
Perioperative epidural analgesia and recurrence-free survival for ovarian cancer surgery: A retrospective analysis. 2013
Phase I trial of trebananib (AMG 386) plus temsirolimus (Tr plus T) in patients (pts) with advanced solid tumors (PJC-008/NCI#9041) 2013
Prevalence, risk factors, treatment and outcomes of catheter-related thrombosis in patients with malignancies. 2013
Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study-NCT00811369. 2013
Rapid assessment of frailty prior to treatment of elderly colorectal cancer patients. 2013
Rapid assessment of frailty prior to treatment of elderly colorectal cancer patients. 2013
Real-time clinical application of next-generation sequencing (NGS): Results from a multicenter program 2013
Reasons for delay in time to initiation of adjuvant chemotherapy (AC) for colon cancer (CC). 2013
Results from a structured interprofessional palliative care rehabilitation program in oncology. 2013
Risk and predictors of suicide in colorectal cancer patients: A SEER analysis 2013
Screening for Lynch syndrome in unselected women with endometrial cancer 2013
Simulating the cost-effectiveness of lung cancer screening by low-dose CT scan in Canada 2013
Switching patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with residual disease on long-term imatinib (IM) to nilotinib (NIL): ENESTcmr 24-mo follow-up 2013
The effect of surgery type on survival and recurrence in very young women with breast cancer. 2013
The first 10 years experience with genetic testing (GT) for BRCA1/2 mutations in a publicly funded program at a tertiary care teaching hospital in Ontario, Canada 2013
The role of FSH in castration-induced adipogenesis: Highlighting differences between orchiectomy, GNRH agonists, and antagonists. 2013
Thrombotic events in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab. 2013
Toward integration of palliative care into cancer care: A study on profile of psychosocial and clinical complications among attendees of a Nigerian oncological center. 2013
Weekly vinblastine in chemotherapy-naive children with unresectable or progressive low grade glioma: A Canadian cooperative study 2013
A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC). 2013
Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC). 2013
Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy. 2013
Study of the impact of Charlson comorbidity index and hypertension on survival in patients with metastatic castration-resistant prostate cancer. 2013
Classification of a VUS in MLH1 using a combination of family segregation studies and protein biochemistry. 2013
Quality of life in a multicenter phase II trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma. 2013
Reasons for delay in time to initiation of adjuvant chemotherapy (AC) for colon cancer (CC). 2013
Thrombotic events in patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab. 2013
Patient-centered wait time measurement in Ontario. 2012
Robotic radiosurgery for the treatment of one to three brain metastases: A pragmatic application of cost-benefit analysis using willingness to pay. 2012
Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. 2012
A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575) 2012
A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). 2012
A phase II study of RO4929097 (RO), a gamma-secretase inhibitor, in advanced platinum (Pt)-resistant (R) ovarian cancer (OC): A study of the PMH, Chicago, and California phase II consortia 2012
A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). 2012
A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). 2012
A phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6). 2012
A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29 2012
A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC) 2012
A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC). 2012
Cognitive function and fatigue in colorectal cancer (CRC) patients: A prospective longitudinal controlled study 2012
Do patient-reported symptoms predict for emergency department visits? A population-based analysis 2012
Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). 2012
Feasibility and acceptability of patient-reported outcomes data collection for clinical care following breast reconstruction. 2012
History of autoimmunity to predict clinical response to DNA methyltransferase inhibitors (DNMTI) in myelodysplastic syndromes (MDS), and MDS-derived acute myeloid leukemias (AML). 2012
Impact of concurrent (CON) and sequential (SEQ) radiotherapy (RT) with adjuvant aromatase inhibitors (AI) in early-stage breast cancer (EBC): NCIC CTG MA.27. 2012
Insurance status and cancer disparities in adolescents and young adults age 15 to 39: National Cancer Data Base, 1998-2003. 2012
Low-level laser therapy for chemotherapy-induced peripheral neuropathy. 2012
NCIC IND.190: A phase I trial of MK-0646 in combination with cisplatin and etoposide in extensive-stage small cell lung cancer (ES SCLC). 2012
Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study. 2012
Once-daily oral afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: A phase I dose escalation trial. 2012
Once-daily oral afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: A phase I dose escalation trial. 2012
Oncology education in Canadian undergraduate and postgraduate medical programs: A survey of educators and learners 2012
Patient-reported cognitive impairments among women with breast cancer randomly assigned to hormonal therapy (HT) alone versus chemotherapy followed by hormonal therapy (C plus HT): Results from the Trial Assigning Individualized Options for Treatment (TAILORx) 2012
Patient-reported satisfaction with reconstructed breasts in the long-term survivorship period: Comparison of autologous and nonautologous breast reconstruction 2012
Positron emission tomography/computed tomography (PET/CT) for the diagnosis of recurrent cancer (PETREC): A multicenter, prospective cohort study. 2012
Predicting sensitivity to azacytidine in non-small cell cancer lines by absence of activating mutations. 2012
Predicting sensitivity to azacytidine in non-small cell cancer lines by absence of activating mutations. 2012
Pretreatment neurocognitive function (NCF) status in head and neck cancer (HNC) patients (pts) with comparison to control cohort 2012
Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial 2012
Quantitative immunohistochemical (IHC) assessment of ataxia-telangiectasia mutated (ATM) in estrogen receptor (ER) negative early breast cancer (BC). 2012
Results of a cluster randomized trial to evaluate a nursing lead supportive care intervention in newly diagnosed breast and colorectal cancer patients. 2012
Stage III NSCLC: How many patients are really suitable for radical treatment approaches? 2012
Stage III NSCLC: How many patients are really suitable for radical treatment approaches? 2012
Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up 2012
The value of personalizing medicine: Medical oncologists' and patients' perspectives on genomic testing of breast tumors in chemotherapy treatment decisions 2012
Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy. 2012
Utility of the Edmonton Frail Scale (EFS) in identifying frail elderly patients during treatment of colorectal cancer (CRC) 2012
Utility of the Edmonton Frail Scale (EFS) in identifying frail elderly patients during treatment of colorectal cancer (CRC). 2012
Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes 2012
A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. 2012
Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC). 2012
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). 2012
Testosterone suppression: Impact of testosterone level on disease progression in advanced prostate cancer. 2012
Perioperative chemotherapy for upper gastrointestinal cancer: Correlation between response to treatment and outcome. 2012
Survival analysis of PETCAM: A multicenter randomized controlled trial of PET/CT versus no PET/CT for patients with resectable liver colorectal adenocarcinoma metastases. 2012
NCIC-CTG MA. 20: An intergroup trial of regional nodal irradiation in early breast cancer 2011
The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study 2011
A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors. 2011
A phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer. 2011
A phase III randomized trial of metformin versus placebo on recurrence and survival in early-stage breast cancer (BC) (NCIC Clinical Trials Group MA.32). 2011
A randomized phase III trial of magic mouthwash and sucralfate versus benzydamine hydrochloride for prophylaxis of radiation-induced oral mucositis in head and neck cancer. 2011
A randomized, double-blind, placebo-controlled cross over trial of the effect on quality of life (QOL) of continuing dexamethasone beyond 24 hours following moderately emetogenic chemotherapy in women with breast cancer. 2011
Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP). 2011
Adjuvant sunitinib (Su) for locally advanced esophageal cancer (LAEC): Results of a phase II trial. 2011
An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma metastases (CAM) 2011
An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival. 2011
Bevacizumab (Bev)-based therapy for patients (pts) with colorectal cancer (CRC): McGill University and Segal Cancer Centre experience. 2011
Canadian cancer risk management model: A new health policy tool useful in policy decisions related to lung cancer. 2011
Concordance with NCCN practice guidelines for local therapies as a measure of quality of care: Review of practice and identification of quality gaps. 2011
Cost-effectiveness of a survivorship care plan for breast cancer survivors. 2011
Do high symptom scores trigger clinical actions by providers? Assessing the effect of standardized symptom screening. 2011
Does removal of the primary tumor in patients with metastatic breast cancer improve either local control or overall survival? 2011
Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC). 2011
Evaluation of second-line response to targeted therapy following progression on first-line cediranib, an oral pan-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), in advanced renal cell carcinoma (RCC). 2011
Expected benefits versus actual outcomes in oncology phase III randomized controlled trials (RCTs). 2011
Exposure-response (E-R) analysis to facilitate phase III (P3) dose selection for ganitumab (GAN, AMG 479) in combination with gemcitabine (G) to treat metastatic pancreatic cancer (mPC) 2011
Funding academic oncology clinical trials. 2011
Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC). 2011
How often are opioids prescribed for cancer patients reporting pain? Results of a population-based analysis. 2011
Impact of a change of body mass index (BMI) on outcome following adjuvant endocrine therapy, chemotherapy, or trastuzumab for breast cancer. 2011
Impact of increased use of adjuvant chemotherapy in non-small cell lung cancer: A population and economic assessment. 2011
Incident cancers in people with dysglycemia and other cardiovascular risk factors: Cohort study of the ORIGIN trial. 2011
NCIC CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer. 2011
Neurocognitive function (NCF) in patients (pts) treated with chemo/bio-radiotherapy (C/B-RT) for head and neck cancers (HNC). 2011
Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors. 2011
Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192. 2011
Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). 2011
Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG)MA.31/GSK EGF 108919). 2011
Population-based health care cost estimates related to breast cancer by staging. 2011
Randomized controlled trials (RCTs) in the era of molecular oncology: Methodology, biomarkers, and endpoints. 2011
Randomized trial of a lifestyle intervention for women with early-stage breast cancer (BC) receiving adjuvant hormone therapy: Initial results. 2011
Results of an Ontario Clinical Oncology Group (OCOG) prospective cohort study on the use of FDG PET/CT to predict the need for neck dissection following radiation therapy of head and neck cancer (HNC). 2011
Sponsor/research ethics boards (REB) communications about informed consent (IC) and time to local activation (LA): An NCIC CTG pilot study. 2011
The impact of dose intensity on the efficacy of gemcitabine plus carboplatin (GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): A retrospective analysis of AGO-OVAR 2.5. 2011
The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC.CTG MA.5 randomized trial. 2011
The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study 2011
Tolerability and efficacy of chemotherapy in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. 2011
Translation of evidence into funding policy: An overview of guidelines from the Cancer Care Ontario's Program in Evidence-Based Care (PEBC). 2011
miR128 and LET-7 microRNAs as potential biomarkers for selection of patients with metastatic colorectal cancer candidate to cetuximab/panitumumab therapy. 2011
Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC). 2011
Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. 2011
Initial report of RTOG 9601, a phase III trial in prostate cancer: Effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3,N0 disease and elevated PSA levels 2011
Neoadjuvant temsirolimus in high-risk renal cell carcinoma: Results from a single-center prospective study. 2011
Results of a phase II study of single-agent nab-paclitaxel in platinum-refractory second-line metastatic urothelial carcinoma (UC) 2011
Exposure-response (E-R) analysis to facilitate phase III (P3) dose selection for AMG 479 (A479) in combination with gemcitabine (G) to treat metastatic pancreatic cancer (mPC). 2011
Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer 2010
A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC) 2010
A microarray approach to identify vorinostat-restored signaling pathways in leukemia cells. 2010
A phase II study of single-agent nab-paclitaxel as second-line therapy in patients with metastatic urothelial carcinoma. 2010
A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia 2010
A phase II trial of the Src kinase inhibitor AZD0530 in patients with metastatic or locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A trial of the PMH phase II consortium. 2010
A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC) 2010
A prospective study to evaluate the role of 2-[¹⁸f] fluoro-2-deoxy-d-glucose (FDG)-positron emission tomography (PET), breast magnetic resonance imaging (MRI), and breast ultrasonography in monitoring tumor responses in patients with locally advanced breast cancer (LABC) undergoing neoadjuvant chemotherapy. 2010
A randomized crossover trial of venlafaxine (V) versus gabapentin (G) for hot flashes (HF) in breast cancer survivors. 2010
A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer. 2010
AMG 479 in relapsed or refractory Ewing's family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): Phase II results. 2010
Accuracy of computerized tomography (CT) imaging in predicting pathologic stage for patients undergoing surgery for transitional cell carcinoma (TCC) of the bladder. 2010
Adequacy of data provision and analysis in oncology phase III trials over the past 5 years. 2010
Breast cancer survivors perception of family physician (FP) or specialist as principal provider of routine follow-up care. 2010
Can elderly patients with recurrent ovarian cancer (ROC) be treated with a platinum-based doublet? Results from the CALYPSO trial. 2010
Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. 2010
Clinically significant delayed cardiac morbidity following ABVD chemotherapy for Hodgkin lymphoma: A population-based study 2010
Consistency in reporting of primary endpoints (PEP) from registration to publication for modern randomized oncology phase III trials. 2010
Early stopping rules employing early progression and response compared with conventional stopping rules in actual phase II trials. 2010
Final results of a phase II study of voreloxin in women with platinum-resistant ovarian cancer. 2010
Inconsistencies among lists of cautioned/prohibited drugs in oncology phase I and phase II trials. 2010
Individualized patient care: Are we ready to meet the challenges for patients with lung cancer? 2010
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX327 study. 2010
Interleukin-21 (IL-21) activity in patients (pts) with metastatic melanoma (MM). 2010
Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: Safety and response results from a multicenter phase II trial. 2010
Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors. 2010
Phase I trial of OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): Final results. 2010
Phase I/II study of low-dose cytarabine (LDAC) with sorafenib as first-line therapy of elderly patients with AML or high-risk myelodysplastic syndrome (MDS). 2010
Phase II study of neoadjuvant and adjuvant gefitinib (G) with neoadjuvant chemoradiotherapy (CRT) in operable esophageal adenocarcinoma (EAC). 2010
Phase II study of vorinostat in patients with advanced melanoma. 2010
Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) 2010
Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). 2010
Preventing patupilone-induced diarrhea with high-dose corticosteroids. 2010
Survival of non-small cell lung cancer (NSCLC) patients in a randomized trial as predicted by the FDG-PET standardized uptake value (SUV). 2010
Tamoxifen versus tamoxifen plus octreotide LAR as adjuvant therapy for early-stage breast cancer in postmenopausal women: Update of NCIC CTG MA14 trial. 2010
Temsirolimus (TEM) in endometrial cancer: Predictors of response and progression. 2010
Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial. 2010
Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163 2009
A phase II study evaluating the safety and efficacy of patupilone in patients with platinum refractory/resistant ovarian, primary fallopian, or peritoneal cancer 2009
A phase II study of patupilone in patients (pts) with metastatic castration- resistant prostate cancer (CRPC) who have progressed after docetaxel 2009
A phase II study of patupilone in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel 2009
A phase II study of single agent abraxane as second-line therapy in patients with advanced urothelial carcinoma 2009
A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the PMH Phase II Consortium 2009
A phase II trial of voreloxin in women with platinum-resistant ovarian cancer 2009
A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer 2009
Case report of a 27-year-old male with DCIS 2009
Comparison of randomized phase II studies (RP2s) and subsequent randomized controlled studies (RCTs) using identical systemic therapies 2009
Cost-effectiveness of cetuximab for the first-line treatment of squamous cell carcinoma of the head and neck (SCCHN) in Canada 2009
Cost-effectiveness of cetuximab for the first-line treatment of squamous cell carcinoma of the head and neck (SCCHN) in Canada 2009
Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: A phase II randomized study 2009
Differences in uptake of postoperative adjuvant chemotherapy for lung cancer: Results from the Project for an Ontario Women's Health Evidence-Based Report Card (POWER) study 2009
Economic guidelines for oncology products: Adaptation of the Canadian Agency for Drugs and Technologies in Health (CADTH) technology assessment guidance document 2009
Effect of geographic distance from a cancer centre on choice of systemic therapy in metastatic colorectal cancer 2009
Effect of geographic distance from a cancer centre on choice of systemic therapy in metastatic colorectal cancer 2009
Hypertension (HTN) in National Cancer Institute of Canada Clinical Trials Group study BR.24: A randomized, double-blind phase II trial of carboplatin (C) and paclitaxel (P) with either daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo, in patients with advanced non-small cell lung cancer 2009
Impact of positron emission tomography (PET) in stage III non-small cell lung cancer (NSCLC): A prospective randomized trial (PET START) 2009
Importance of stratification when measuring quality of care: Results from the Project for an Ontario Women's Health Evidence-Based Report Card (POWER) study 2009
Integration between primary care providers and the cancer system: Gaps and opportunities 2009
Interim analysis of a phase II trial of 5-azacitidine (5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer (NSCLC) 2009
Interim analysis of a phase II trial of 5-azacitidine (5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer (NSCLC) 2009
Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer 2009
Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer 2009
OGX-427, a 2 ' methoxyethyl antisense oligonucleotide (ASO), against HSP27: Results of a first-in-human trial 2009
OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against HSP27: Results of a first-in-human trial 2009
PET-CT compared to invasive mediastinal staging in non-small cell lung cancer (NSCLC) 2009
Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias 2009
Phase I study of intravenous decitabine in combination with oral vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas (NHL) 2009
Phase II study of AVR118 in the management of cancer related anorexia/cachexia 2009
Phase II study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer 2009
Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC) 2009
Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC) 2009
Predictors of recurrent thrombosis and anticoagulant-related bleeding in patients with cancer 2009
Primary tumor and patient characteristics in breast cancer as predictors of adjuvant chemotherapy regimen: A regression model 2009
Sorafenib and radiation: A promising combination in colorectal and pancreas cancer 2009
The McGill Cancer Nutrition and Rehabilitation Program 2009
The management of dysphagia in esophageal cancer patients undergoing neoadjuvant chemotherapy: Is invasive tube feeding required? 2009
Treatment and outcome of patients with brain metastases from non-small cell lung cancer (NSCLC) 2009
Trends in the application of dynamic allocation methods in multiarm cancer clinical trials 2009
Two-years biochemical failure-free survival following high intensity focused ultrasound (HIFU) for localized prostate cancer: Prospective single center study of 196 patients 2009
Willingness of breast cancer survivors to participate in a randomized controlled trial (RCT) of digital mammography with or without magnetic resonance imaging (MRI) as breast cancer (BC) surveillance: A feasiblity study 2009
Comparison of Referring and Final Pathology for Patients With Non-Hodgkin's Lymphoma in the National Comprehensive Cancer Network 2008
A comparison of internet-based models assessing the likelihood of a BRCA mutation 2008
A multicenter, open-label, phase I/II study in patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with L-BLP25: 2-year survival and safety results 2008
A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) 2008
A phase I study of concurrent pemetrexed (P)/cisplatin (C)/radiation (RT) for unresectable stage IIIA/B non-small cell lung cancer (NSCLC) 2008
A phase II prospective study of standardized steroid dosing for patients with brain metastases undergoing whole brain radiotherapy 2008
A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1^st-line docetaxel therapy 2008
A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial 2008
A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel 2008
A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel 2008
A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b 2008
A phase II trial of SNS-595 in women with platinum resistant epithelial ovarian cancer 2008
A phase II trial of the histone deacetylase inhibitor belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A PMH phase II consortium trial 2008
A prospective study evaluating ¹⁸F-Fluorodeoxyglucose (¹⁸FDG) positron emission tomography (PET) in the assessment of axillary nodal spread in women undergoing sentinel lymph node biopsy (SLNB) for breast cancer 2008
A randomized controlled trial (RCT) of ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography (PET) versus conventional imaging (CI) in staging potentially resectable non-small cell lung cancer (NSCLC) 2008
Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium 2008
Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium 2008
Analysis of immunohistochemical predictors of outcome in pseudomyxoma peritonei 2008
Anticoagulation and bleeding: A pooled analysis of lung cancer trials of the National Cancer Institute of Canada Clinical Trials Group 2008
Clinical safety and efficacy of ⁹⁰yttrium resin microspheres alone in unresectable, heavily pre-treated colorectal liver metastases: results of a phase II trial 2008
Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials 2008
Construction of tissue micro array from prostate needle biopsies using vertical clustering re-arrangement technique 2008
Correlation of computerized tomography measurement of visceral adiposity with plasma adiponectin levels and presence of metastatic disease in patients with clear cell renal cell carcinoma 2008
Correlation of deviation from intended cisplatin (CDDP) dose intensity with outcome in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) receiving concurrent chemoradiation (CRT) 2008
Effects of nutritional intervention in non-small cell lung cancer patients with different levels of systemic inflammation 2008
Expanded phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors 2008
Generalizability of results from oncology clinical trials: Toxicity of irinotecan-based regimens in patients with metastatic colorectal cancer 2008
Health preference instruments in a breast cancer population: Is there a ceiling effect when compared to the quality-of-life instruments? 2008
Impact of a community-based pediatric oncology nursing model 2008
Impact of clinical and molecular predictors of benefit from erlotinib in advanced non-small cell lung cancer on cost-effectiveness 2008
Influence of independent review committees (IRC) on assessment of response rate and progression free survival in phase III clinical trials 2008
Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear cell carcinoma of the kidney 2008
Meta-analysis examining the efficacy of serotonin and/or norepinephrine reuptake inhibitors in the treatment of women with hot flashes 2008
NCIC-CTG MA14 Trial: Tamoxifen (tam) vs. tam plus octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast cancer 2008
Patterns of adjuvant systemic therapy in elderly with breast cancer (BC) 2008
Pharmacokinetic (PK) analysis of a phase I trial investigating continuous treatment with the angiokinase inhibitor BIBF 1120 combined with pemetrexed in previously treated patients with non-small cell lung cancer (NSCLC) 2008
Phase I trial of 5-azacitidine (5AC) and SNDX-275 in advanced lung cancer (NSCLC) 2008
Presentation of non-final results of randomized controlled trials (RCTs) at major oncology meetings 2008
Progression free survival in patients with metastatic and recurrent renal cancer treated with sorafenib—Single center experience 2008
Sex, income and age-related differences in colorectal cancer care: results from the Project for an Ontario Women's Health Evidence-based Report Card (POWER) study 2008
Sorafenib (SOR) in patients (pts) with advanced/recurrent uterine carcinoma (UCA) or carcinosarcoma (CS): A phase II trial of the University of Chicago, PMH, and California Phase II Consortia 2008
The quality of informed consent forms for oncology clinical trials 2008
The unclear zone in phase II clinical trials 2008
Triple-negative receptor status and prognosis in the NCIC CTG MA. 21 adjuvant breast cancer trial 2008
Consistency of Phase III Clinical Trial Abstracts Presented at an Annual Meeting of the American Society of Clinical Oncology Compared With Their Subsequent Full-Text Publications 2008
Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia 2008
Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer 2007
Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma 2007
A multi-centre, open-label study to assess the safety of Stimuvax (BLP25 liposome vaccine or L-BLP25) in non-small cell lung cancer (NSCLC) patients (pts) with unresectable stage III disease 2007
A phase 1 study of the selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms 2007
A phase 1 study of the selective cyclin dependent kinase inhibitor P276–00 in patients with advanced refractory neoplasms 2007
A phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors 2007
A phase III adjuvant trial of sequenced EC plus filgrastim plus epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA.21) 2007
A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC) 2007
A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC) 2007
A randomized trial of computer and pamphlet-based versions of the Decision Board (DB) 2007
A review of 565 phase II trial abstracts from ASCO 2005: Design characteristics of contemporary trials evaluating cytotoxic versus non-cytotoxic regimens 2007
A single agent, phase I pharmacodynamic study of nimotuzumab (TheraClM-h-R3) in patients with advanced refractory solid tumors 2007
A tool for assessing adverse events in phase I/II oncology clinical trials 2007
Adherence to surveillance guidelines following curative resection for stage II and III colorectal cancer 2007
CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib-A trial of the PMH Phase II Consortium 2007
Changes in estrogen receptor (ER), progesterone receptor (PR) and HER2/neu status with time: Discordance rates between primary and metastatic breast pathology samples 2007
Cognitive function and fatigue in cancer patients after chemotherapy: A longitudinal cohort study in patients with colorectal cancer (CRC) 2007
Correlation between changes in 2-or 3-year disease-free survival (DFS) and 5-year overall survival (OS) in adjuvant breast cancer trials from 1966-2006 2007
Descriptive study on the lost productivity in breast cancer patients 2007
Determining knowledge transfer gaps in the life cycle of evidence for chemotherapy in non-small cell lung cancer (NSCLC) through cumulative meta-analysis 2007
Identification of cancer care and protocol characteristics associated with recruitment rate in breast cancer clinical trials in Ontario 2007
Initial versus recent outcomes with a non-risk adapted surveillance policy in stage I non-seminomatous germ cell tumors (NSGCT) 2007
Lack of effect of prophylactic hematopoeitic colony stimulating factors in cancer patients and stem cell transplant recipients on short term survival: A meta-analysis of randomized trials 2007
Mechanisms of bone metastasis (BM) growth in patients with metastatic breast cancer (MBC): An exploratory study 2007
Nomograms to predict serious adverse events (SAEs) in patients (pts) enrolled in phase II clinical trials of molecularly targeted agents (MTAs) 2007
Novel and existing mutations in the EGF receptor tyrosine kinase domain are predictors of optimal resectability (OR) in malignant peritoneal mesothelioma (MPM) 2007
PRODIGE: A phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma 2007
Pediatric phase I trial and pharmacokinetic (PK) study of dasatinib: A report from the Children's Oncology Group 2007
Phase II stopping rules employing response rates and early progression 2007
Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium 2007
Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium 2007
Predictors of toxicity to concurrent chemoradiation (CRT) in patients (pts) with locally advanced head and neck squamous cell cancer (HNSCC) 2007
Predictors of toxicity to concurrent chemoradiation (CRT) in patients (pts) with locally advanced head and neck squamous cell cancer (HNSCC) 2007
Prospective study of specialist oncology community nursing resulting in improvements in key patient supportive care outcomes 2007
Quality and consistency of phase III clinical trial abstracts presented at an Annual Meeting of the American Society of Clinical Oncology compared with their subsequent full-text publications 2007
Quality and consistency of phase III clinical trial abstracts presented at an Annual Meeting of the American Society of Clinical Oncology compared with their subsequent full-text publications 2007
Reliability of data collection for the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multi-center outcomes database: A methodological approach 2007
Screening cancer patients for clinical trial eligibility: A randomized study 2007
Tamoxifen (T) compared to placebo (P), after adjuvant chemotherapy (CT), in premenopausal women with early breast cancer (EBC): Interim results of NCIC-CTG MA.12 2007
The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Subset analysis of patients (pts) with brain metastases (BM) 2007
The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Subset analysis of patients (pts) with brain metastases (BM) 2007
The quality of phase I trial (P1T) abstracts submitted to ASCO meetings 2007
Use of systemic therapy in women with recurrent ovarian cancer-Development of a national clinical practice guideline 2007
W Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival of the TAX 327 study 2007
What can physicians do to promote patient involvement in decision making (DM) in the oncology consultation? 2007
Evaluation of Cognitive Function Associated With Chemotherapy: A Review of Published Studies and Recommendations for Future Research 2007
Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study 2007
Favorable Outcome for Adolescents With Acute Lymphoblastic Leukemia Treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols 2007
Impact and Perceptions of Mandatory Tumor Biopsies for Correlative Studies in Clinical Trials of Novel Anticancer Agents 2006
A comparison of BRCA1 and BRCA2 risk assessment models. 2006
A comparison of patient and physician attributes that promote patient involvement in treatment decision making in the oncology consultation. 2006
A dose and schedule optimizing evaluation of MG98 given as either a 2 hour IV infusion twice weekly or as a 7 day continuous infusion in combination with interferon alpha (INF) in nephrectomized patients (pts) with advanced renal cell carcinoma (RCC) 2006
A phase II study of lapatinib in recurrent or metastatic EGFR and/or ErbB2 expressing adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT) 2006
A phase II study of lapatinib in recurrent or metastatic EGFR and/or ErbB2 expressing adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT). 2006
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first line treatment in hormone refractory prostate cancer (HRPC) 2006
A randomized controlled trial (RCT) of long-term follow-up for early stage breast cancer comparing family physician to specialist care: A report of secondary outcomes. 2006
A randomized controlled trial to evaluate the impact of an educational DVD an cancer patients considering participation in a phase I clinical trial. 2006
Agreement between physicians and patients about what constitutes shared decision making. 2006
Angiagenesis pathway gene polymorphisms associated with clinical outcome in recurrent ovarian cancer treated with low dose cyclophosphamide and bevacizumab: A California Consortium Trial. 2006
Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study. 2006
Bortezomib is active in Waldenstrom's Macroglobulinemia (WM) - Results of a National Cancer Institute of Canada (NCIC) phase II study in previously untreated or treated WM. 2006
Cognitive impairment associated with chemotherapy for breast cancer: An exploratory case-control study. 2006
Cytokine levels in patients (pts) with localized colorectal cancer (CRC) after surgery and their relationship to fatigue and cognitive function. 2006
Delays in diagnosis and initiating treatment for patients with lung cancer. 2006
Direct decompressive surgery with post-operative radiotherapy (S+RT) versus radiotherapy (RT) alone for the treatment of metastatic epidural spinal cord compression (MESCC): A cost-utility analysis using Ontario health economic data. 2006
Dose banding of chemotherapy doses at the Juravinski Cancer Centre. 2006
Effects of adjuvant chemotherapy on the protein C anticoagulant pathway in patients with early stage breast cancer. 2006
Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C) plus paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): A study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). 2006
Gemcitabine (G) and vinorelbine (V) in patients (pts) with recurrent advanced non-small cell lung cancer (NSCLC): Sequence of administration matters 2006
Long-term results of concurrent gemcitabine (G) and radiotherapy (GRT) for locally advanced (LA) or high-risk resected (R) pancreatic cancer. 2006
Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer - NCICIND 160. 2006
NCICCTG MA.17: Tolerability of letrozole among ethnic minority women. 2006
Neuroendocrine tumors (NET) of the gastrointestinal tract: A decade of experience at the Princess Margaret Hospital. 2006
Optimizing the design and distribution of clinical trial information via handheld devices. 2006
Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial 2006
Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP). 2006
Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial. 2006
Predicting recurrence following post-chemotherapy retroperitoneal lymph node dissection for residual fibrosis or teratoma. 2006
Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). 2006
Quality of life (QOL) of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) following treatment with docetaxel or mitoxantrone in the TAX-327 study. 2006
Randomized clinical trials in oncology stopped early for benefit (RCTSEB). 2006
Understanding and preferences for receiving prognostic information: A comparison of the views of Australian and Canadian patients with metastatic cancer 2006
Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer 2006
Comparison of Outcomes of Phase II Studies and Subsequent Randomized Control Studies Using Identical Chemotherapeutic Regimens 2005
Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer 2005
A multicenter, phase II study of cisplatin, irinotecan and epirubicin (PIE) administered every 3 weeks in patients with unresectable, locally advanced/metastatic cervical carcinoma. 2005
A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCIC CTG IND.154 2005
A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCICCTG IND. 154. 2005
A phase II study of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC). 2005
A phase II study of UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A Princess Margaret Phase II Consortium Trial 2005
A phase II study of triapine in combination with gemcitabine in advanced pancreatic carcinoma: A Princess Margaret Hospital phase II consortium trial. 2005
A phase II trial of perifosine as second line therapy for advanced pancreatic cancer. A study of the Princess Margaret Hospital [PMH] phase II consortium. 2005
A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas (NECs). 2005
Determinants of preferences for starting extended adjuvant letrozole (L) in postmenopausal women following five years of tamoxifen. 2005
Dose reduced first-line capecitabine monotherapy in older and less fit patients with advanced colorectal cancer (ACRC) 2005
Evaluation of responsiveness to change to psychosocial group therapy (PGT) and to the process of dying of psychosocial and quality of life (QOL) measures. 2005
HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial 2005
HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial. 2005
Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial. 2005
Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors. 2005
Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the princess margaret hospital [PMH] phase II consortium. 2005
Phase II study of oblimersen sodium and rituximab in patients with recurrent B-cell non-Hodgkin's lymphoma. 2005
Pre-radiation R115777 in patients with newly diagnosed glioblastoma multiforme and residual enhancing disease 2005
Predictive value of eTag dimerization assay in patients with metastatic colorectal cancer treated with erlotinib. 2005
Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC). 2005
Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC). 2005
S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results 2005
S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results. 2005
The effect of doxycycline on bone turnover and tumor markers in breast cancer (BC) patients with skeletal metastases 2005
The effect of doxycycline on bone turnover and tumor markers in breast cancer (BC) patients with skeletal metastases. 2005
The impact and perception of mandatory tumor biopsies (Bx) for correlative studies in clinical trials of novel anticancer agents. 2005
What are the supportive care service needs of recently diagnosed cancer patients? Results of a population based study 2005
Willingness of older people with cancer to participate in cancer clinical trials is not a barrier to accrual. 2005
Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial 2005
Why Cancer Patients Enter Randomized Clinical Trials: Exploring the Factors That Influence Their Decision 2004
A phase 2, single agent study of Cl-1033 administered at two doses in ovarian cancer patients who failed platinum therapy. 2004
A randomized controlled trial (RCT) of routine follow-up for early stage breast cancer: A comparison of primary care versus specialist care. 2004
A randomized phase I clinical and biologic study of two schedules of BAY 43-9006 in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): A National Cancer Institute of Cancer Clinical Trials Group Study. 2004
Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen 2004
Cancer patients and the Internet: A randomized controlled trial (RCT) evaluating an intervention to facilitate physician and patient information exchange from the Internet (I). 2004
Characteristics of out-of-pocket costs for cancer patients in Ontario, Canada 2004
Chemo-radiotherapy versus radiotherapy alone for nasopharyngeal carcinoma: A meta-analysis of 78 randomized controlled trials (RCTs) from English and non-English databases. 2004
Comparison of outcomes of phase II trials (P2Ts) and subsequent randomized control trials (RCTs) using identical therapeutic regimens. 2004
Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: A National Cancer Institute of Canada Clinical Trials Group Study: MY.7. 2004
Experience with sentinel lymph node biopsy for eyelid and conjunctival malignancies. 2004
Frequency of axillary node dissection and chemotherapy in breast cancer patients over 60 years of age compared with those younger than 60 years of age. 2004
Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA).: Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCICCTG and the EORTC GCG. 2004
Ontario Cancer Research Ethics Board (OCREB): A central research ethics board initiative. 2004
Patterns of trastuzumab (T) use in three Canadian provinces. 2004
Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL) 2004
Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL) 2004
Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL) 2004
Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCICCTG IND-148. 2004
Prognostic factors in early stage head and neck squamous cell carcinoma (HNSCC) patients in a prospective clinical trial. 2004
Prognostication using serum levels of components of the folate metabolic pathway in patients (PTS) treated with capecitabine for advanced colorectal cancer (ACRC). 2004
Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR. 18. 2004
Retrospective analysis of treatment practices for elderly cancer patients (Pts) in Ontario, Canada 2004
Safety and efficacy of DHA-paclitaxel (TXP) in non-small cell lung cancer (NSCLC). 2004
Slow intravenous infusion of PV701, an oncolytic virus: Final results of a phase I study 2004
Slow intravenous infusion of PV701, an oncolytic virus: Final results of a phase I study 2004
Slow intravenous infusion of PV701, an oncolytic virus: Final results of a phase I study 2004
Supportive care in cancer. Who does what? 2004
The intensity of CEACAM-1 expression in melanoma patients and the timing of treatment with recombinant human interferon & 2b showed correlation with survival. 2004
Thromboembolism (TE) in children with acute lymphoblastic leukemia (ALL) treated on Dana Farber Cancer Institute (DFCI) protocols: Effect of dose and type (prednisone versus dexamethasone) of steroids used. 2004
Tolerability of the Intergroup 0099 regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. 2004
Are Older Cancer Patients Being Referred to Oncologists? A Mail Questionnaire of Ontario Primary Care Practitioners to Evaluate Their Referral Patterns 2003
Enzyme-linked immunoabsorbent assay-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort. 1998
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update.. JCO2500007. 2025
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.. 43:1083-1100. 2025
A prospective provincial registry of PSMA PET CT for recurrent prostate cancer (PREP): Results for 4135 men.. 43. 2025
Association between abnormal IMDC laboratory criteria after surgery and cancer-specific and overall survival in non-metastatic renal cell carcinoma: Potential biomarkers for adjuvant therapy patient selection.. 43:567-567. 2025
Association between sociodemographic marginalization and receipt of intensified treatment for metastatic castrate-sensitive prostate cancer.. 43. 2025
Bone metastases and use of bone protective agents (BPA) for metastatic renal cell carcinoma (mRCC): A contemporary national real-world analysis.. 43. 2025
Cabozantinib real-world effectiveness in the second-line setting of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. 43. 2025
Concomitant G-CSF use in maintaining an efficacious dose and safe delivery of docetaxel in combination with darolutamide in patients with metastatic hormone sensitive prostate cancer (mHSPC): ARASENS, a phase 3 study.. 43. 2025
Decipher score as a predictor of response to treatment intensification in the NRG Oncology-RTOG 0534 (SPPORT) phase III randomized post-prostatectomy salvage radiotherapy trial.. 43. 2025
Frailty and adverse clinical outcomes in prostate cancer patients: An analysis from the RADICAL-PC cohort.. 43. 2025
Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials.. 43. 2025
Hypofractionated radiotherapy for prostate cancer (HYDRA): An individual patient data meta-analysis of randomized trials in the MARCAP consortium.. 43. 2025
Management strategies and patient outcomes among LPC patients with persistently positive PSA after RP.. 43. 2025
Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS 9).. 43:22-22. 2025
OCOG-RATIONAL: A phase II randomized trial of optimal recurrence-directed therapy (RDT) without or with androgen-deprivation therapy (ADT) in radio-recurrent oligo-metastatic castrate sensitive prostate cancer (romCSPC).. 43:TPS305-TPS305. 2025
OPAR: A Randomized Trial of Partial Breast Irradiation in Five Fractions Once Daily for Early Breast Cancer.. 43:505-512. 2025
PORTOS gene signature as a predictor of risk of adverse events after dose-escalated vs. lower-dose prostate radiation therapy in NRG/RTOG 0126.. 43:375-375. 2025
Population-based assessment of treatment patterns for high-risk localized prostate cancer.. 43. 2025
Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma.. 43. 2025
Relationship between androgen deprivation therapy and kidney function in patients with prostate cancer: An analysis of the RADICAL-PC study.. 43. 2025
The prognostic impact of prostate-specific antigen at 6 months after post-prostatectomy radiotherapy: An individual patient data analysis of two NRG oncology randomized trials.. 43. 2025
Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2.. 43:422-431. 2025
Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.. 43:101-105. 2025
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.. 42:4271-4281. 2024
Exploring cannabis information and perceptions of cannabis harms among patients with cancer.. 20:361-361. 2024
The impact of admitting ward on resource utilization and outcomes among hospitalized cancer survivors.. 20:36-36. 2024
Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole. 42:2887-2898. 2024
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.. 42:2918-2927. 2024
Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer. 42:2377-2381. 2024
Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials. 42:2132-2138. 2024
Results from a randomised, open-label trial of a multimodal intervention (exercise, nutrition and anti-inflammatory medication) plus standard care versus standard care alone to attenuate cachexia in patients with advanced cancer undergoing chemotherapy.. 42:LBA12007-LBA12007. 2024
A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer.. 42:TPS8669-TPS8669. 2024
Adjunctive statistical standardization of quantitated adjuvant ER and PgR in CCTG MA.27.. 42:567-567. 2024
Artemin and immune checkpoint inhibitor (ICI) efficacy in metastatic colorectal cancer (mCRC): A correlative analysis of the Canadian Cancer Trials Group (CCTG) CO.26 trial.. 42:3587-3587. 2024
Association of socioeconomic status with aggressive end-of-life care in patients with cancer before and during the COVID-19 pandemic.. 42:1612-1612. 2024
Atezolizumab + bevacizumab versus lenvatinib as first-line systemic therapy for treatment of hepatocellular carcinoma in a real-world population: Outcomes from the HCC CHORD database.. 42:4111-4111. 2024
Comparing the characteristics and outcomes of hospitalizations between cancer and non-cancer survivors.. 42:12138-12138. 2024
Efficacy of post-lenvatinib treatments in patients (pts) with advanced renal cell carcinoma (aRCC).. 42:4538-4538. 2024
Genomics to select treatment for patients (pts) with metastatic cancer: Final analysis of Molecular Tumor Board (MTB) evaluations in the ROME trial.. 42:3157-3157. 2024
Health state utility assessment for low-grade glioma.. 42:e14039-e14039. 2024
Incidence of venous thromboembolism in newly diagnosed glioblastoma multiforme and associated risk factors: A retrospective chart review.. 42:e14040-e14040. 2024
Mobilizing exercise recommendations for people with bone metastases: An experience-based co-design approach.. 42:e23241-e23241. 2024
Practice patterns of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in real-world Canadian practice.. 42:e16594-e16594. 2024
Predictors of short-term death and long-term survival in advanced hepatocellular carcinoma (HCC) treated with contemporary tyrosine kinase inhibitors (TKI) or immunotherapy: A multicenter analysis from the HCC-CHORD consortium.. 42:4098-4098. 2024
Quality of life (QoL) benefits following ¹⁷⁷Lu-DOTATATE therapy in patients (pts) with ⁶⁸Ga-DOTATATE PET positive primary site agnostic neuroendocrine tumors (NET).. 42:e16291-e16291. 2024
Real-world treatment practices in patients with muscle invasive bladder cancer (MIBC) treated in Alberta, Canada.. 42:e16596-e16596. 2024
Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial.. 42:515-515. 2024
Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study.. 42:104-104. 2024
Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).. 42:4514-4514. 2024
The impact of admitting ward on resource utilization and outcomes among hospitalized cancer survivors.. 42:1550-1550. 2024
What is a bad ALK? A scoping review of molecular markers of poor prognosis.. 42:e20530-e20530. 2024
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. 42:1222-1228. 2024
Impact of timing of immunotherapy and cytoreductive nephrectomy on outcomes in metastatic renal cell carcinoma: Results from the CKCis database.. 42:416-416. 2024
Ipilimumab/nivolumab (I/N) compared to axitinib/pembrolizumab (A/P) in metastatic renal cell carcinoma (mRCC): Insights from a Canadian population.. 42:393-393. 2024
Long-term results of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy (sRT) post prostatectomy.. 42:320-320. 2024
Management, outcomes and predictors of recurrence in chromophobe renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).. 42:389-389. 2024
Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design.. 42:141-141. 2024
Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.. 42:367-367. 2024
Real-world practice patterns, treatment-related toxicity, and survival outcomes in older patients with metastatic renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).. 42:366-366. 2024
Real-world treatment outcomes in patients with advanced renal cell carcinoma who receive axitinib plus pembrolizumab in the first-line setting in Canadian cancer centers.. 42:382-382. 2024
Treatment-free survival after first-line therapies for metastatic renal cell carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis.. 42:390-390. 2024
A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors.. 42:TPS232-TPS232. 2024
BOLD-100-001 (TRIO039): A phase 2 study of BOLD-100 in combination with FOLFOX in patients with advanced mCRC previously treated with FOLFOX/CAPOX—Efficacy and safety analysis.. 42:143-143. 2024
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer. 41:5356-5362. 2023
Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline. 41:5448-5472. 2023
Impact of ¹⁸F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer. 41:3909-3916. 2023
A phase II study of durvalumab re-treatment +/- prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND.238A).. 41:TPS2673-TPS2673. 2023
Assessment of risk of overall and late distant recurrence by Breast Cancer Index in postmenopausal women with early-stage, HR+ breast cancer in the TEAM trial.. 41:509-509. 2023
Association between locoregional failure and NFE2L2/KEAP1/CUL3 pathway mutations in NRG/RTOG 9512: A randomized trial of hyperfractionation vs. conventional fractionation in T2N0 glottic squamous cell carcinoma (SCC).. 41:6054-6054. 2023
Association of socioeconomic status (SES) with use of specialist palliative care (SPC) among people who died with cancer before and during the COVID-19 pandemic.. 41:e18504-e18504. 2023
CCTG EN10: A phase II study of tailored adjuvant therapy in POLE-mutated and p53-wildtype/NSMP early-stage endometrial cancer (EC)—RAINBO BLUE and TAPER.. 41:TPS5632-TPS5632. 2023
Can synthetic data accurately mimic oncology clinical trials?. 41:1554-1554. 2023
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, Influence, CTS-5)? A TEAM Pathology substudy.. 41:533-533. 2023
Education modalities for serious illness communication training: A scoping review on the impact on clinician behavior and patient outcomes.. 41:e24003-e24003. 2023
Evaluating response to interventions for vasomotor symptoms in patients with breast cancer: A patient-centered approach.. 41:e24126-e24126. 2023
Incidence of second primary malignancies (SPMs) in patients with multiple myeloma (MM) receiving anti-CD38 monoclonal antibodies (mAbs): A systematic review and meta-analysis.. 41:e24078-e24078. 2023
Multisystem immune-related adverse events from dual agent immunotherapy use.. 41:2635-2635. 2023
Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).. 41:TPS9160-TPS9160. 2023
Patient-reported outcomes during pelvic radiation therapy: A secondary analysis on sexual function from NRG-RTOG 1203.. 41:5533-5533. 2023
Phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: The INVINCIBLE trial.. 41:573-573. 2023
Plasma arginine as a candidate predictive biomarker for response to immune checkpoint inhibition (ICI) in metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial.. 41:3545-3545. 2023
Prognostic impact of PSA nadir (n) ≥0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.. 41:5002-5002. 2023
Real-world multicentre analysis of patients with hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (A+B): Efficacy, esophagogastroduodenoscopy (EGD) uptake and bleeding complications.. 41:4105-4105. 2023
Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy.. 41:4530-4530. 2023
The FARGO study: Frailty assessment for risk prediction in gynecologic oncology.. 41:tps12137-tps12137. 2023
Use of antibiotics and outcomes of patients presenting to emergency department with non-neutropenic fever and/or suspected infection.. 41:e18693-e18693. 2023
Use of prophylactic and reactive feeding tubes in patients with esophageal cancer: A single-centre cohort study.. 41:e18694-e18694. 2023
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma. 41:2125-2133. 2023
Biochemical disease control outcomes of stereotactic body radiation therapy (SBRT) or moderate hypo-fractionation (HFRT) for low- and intermediate-risk prostate cancer (PrCa): Retrospective analysis of 12 years of experience at two Canadian cancer centers.. 41:363-363. 2023
FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study.. 41:460-460. 2023
First look at the baseline characteristics of participants in IRONMAN, the international registry for men with advanced prostate cancer.. 41:85-85. 2023
Mepitel Film for the Prevention of Acute Radiation Dermatitis in Breast Cancer: A Randomized Multicenter Open-Label Phase III Trial. 41:1250-1264. 2023
Outcomes of partial nephrectomy for non-metastatic cT2 renal tumors: Results from a Canadian multi-institutional collaborative.. 41:690-690. 2023
Patterns of failure after radiotherapy (RT) in patients with prostate cancer re-staged with ¹⁸F-DCFPyL PSMA-PET: A regional cohort analysis.. 41:45-45. 2023
Patterns of failure with ¹⁸F-DCFPyL PSMA PET/CT in the post-prostatectomy setting: A regional cohort analysis.. 41:309-309. 2023
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. 41:TPS750-TPS750. 2023
Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer.. 41:76-76. 2023
Prospective ctDNA genotyping for treatment selection in metastatic castration-resistant prostate cancer (mCRPC): The Canadian Cancer Trials Group phase II PC-BETS umbrella study.. 41:218-218. 2023
Safety and efficacy of immune checkpoint inhibitors (ICI) in advanced penile squamous cell carcinoma (PeCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT).. 41:5-5. 2023
Plasma phosphocreatine (PC) as a predictive biomarker for immune checkpoint inhibition in patients with refractory metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial.. 41:183-183. 2023
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU). 41:43-53. 2023
Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?. 40:3573-3575. 2022
Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative.. 40:332-332. 2022
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline. 40:3310-3322. 2022
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline. 40:3323-3343. 2022
Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601. 40:3172-3179. 2022
LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T₁N₀ luminal A breast cancer (BC).. 40:LBA501-LBA501. 2022
A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.. 40:1102-1102. 2022
BOLD-100-001 (TRIO039): A phase 1b dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastrointestinal solid cancers: Interim safety, tolerability, and efficacy.. 40:3031-3031. 2022
Clinical outcomes associated with azacitidine (AZA) monotherapy for treatment-naïve, higher-risk myelodysplastic syndrome (HR-MDS): A systematic literature review and meta-analysis.. 40:e19062-e19062. 2022
Effects of liver metastases on efficacy of immune checkpoint blockade in treatment refractory, metastatic colorectal cancer (CRC): CCTG CO.26.. 40:3600-3600. 2022
Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative.. 40:e18628-e18628. 2022
Intratumoral (IT) INT230-6 can cause tumor necrosis in vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study).. 40:605-605. 2022
Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin versus placebo in hormone receptor–positive early-stage breast cancer (CCTG MA32).. 40:526-526. 2022
Molecular landscape and actionable alterations in a genomic-guided cancer clinical trial: First analysis of the ROME trial.. 40:3087-3087. 2022
Overall survival of patients with chronic obstructive pulmonary disease receiving immunotherapy for non-small cell lung cancer: A population-based analysis in Ontario, Canada.. 40:e21172-e21172. 2022
Preliminary efficacy of optimal pharmacotherapy and patient views in multiple myeloma.. 40:e20006-e20006. 2022
Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut).. 40:6046-6046. 2022
SALVO: Single-arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.. 40:9573-9573. 2022
Sentinel lymph node biopsy in Merkel cell carcinoma: A multi-institutional study from the Pan-Canadian Merkel Cell Collaborative.. 40:9583-9583. 2022
Treatment outcomes for newly diagnosed, untreated TP53-mutated acute myeloid leukemia: A systematic review and meta-analysis.. 40:e19020-e19020. 2022
Will COVID-19 directives to reduce regularly scheduled physical examinations affect recurrence detection in patients with early breast cancer?. 40:1532-1532. 2022
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. 40:787-800. 2022
BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC).. 40:437-437. 2022
Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study. 39:3453-3462. 2021
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. 39:3496-3505. 2021
Utility of a Cancer Predisposition Screening Tool for Predicting Subsequent Malignant Neoplasms in Childhood Cancer Survivors. 39:3207-3216. 2021
Reporting of tobacco use and impact on outcomes in cancer cooperative group clinical trials: A systematic scoping review.. 39:40-40. 2021
Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. 39:3056-3082. 2021
Choosing optimal therapy for relapsed refractory multiple myeloma: A systematic review and network meta-analysis.. 39:e20037-e20037. 2021
Impact of lenvatinib (LEN) dose-intensity and starting dose on survival among patients with advanced hepatocellular carcinoma (HCC): Results from a Canadian multicenter database (HCC CHORD).. 39:e16142-e16142. 2021
Implementation of virtual mentoring to optimize collection of patient-reported data in the COVID-19 era: A prospective cohort study with adaptive design.. 39:e24091-e24091. 2021
Predictors of clinical trial enrollment and impact on outcome in children and adolescents with acute lymphoblastic leukemia: A population based study.. 39:7031-7031. 2021
Drugging the Master Regulator TP53 in Cancer: Mission Possible?. 39:1595-1597. 2021
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. 39:1040-1091. 2021
Analysis of the effect of crossover from placebo (PBO) to darolutamide (DARO) on overall survival (OS) benefit in the ARAMIS Trial.. 39:240-240. 2021
Efficacy and safety of lenvatinib in the real-world treatment of hepatocellular carcinoma: Results from a Canadian multicenter database (HCC CHORD).. 39:275-275. 2021
Elective Cancer Surgery in COVID-19–Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study. 39:66-78. 2021
Comparing characteristics and outcomes of cancer to non-cancer patients admitted to general internal medicine (GIM).. 38:21-21. 2020
Fostering interspeciality learning in cancer survivorship care: Learning suite results.. 38:59-59. 2020
Hypofractionated Breast Irradiation: What’s Next?. 38:3245-3247. 2020
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN). 38:2993-3002. 2020
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. 38:2830-2838. 2020
Accelerated Partial Breast Irradiation and Intraoperative Partial Breast Irradiation: Reducing the Burden of Effective Breast Conservation. 38:2254-2262. 2020
Protective Effects of Dietary Intake of Antioxidants and Treatment-Related Toxicity in Childhood Leukemia: A Report From the DALLT Cohort. 38:2151-2159. 2020
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. 38:1875-1886. 2020
A multicenter study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of taxotere/cyclophosphamide-induced febrile neutropenia in patients with early-stage breast cancer.. 38:7001-7001. 2020
A phase II multicenter study of stereotactic radiotherapy (SRT) for oligoprogression in metastatic renal cell cancer (mRCC) patients receiving tyrosine kinase inhibitor (TKI) therapy.. 38:5065-5065. 2020
Clinical outcomes of pancreas cancer patients with peritoneal spread: Results from the chord consortium.. 38:e19268-e19268. 2020
Cost-effectiveness of nodal observation versus completion lymphadenectomy in patients with melanoma and sentinel lymph node metastases.. 38:e22076-e22076. 2020
Dissecting outcomes of patients (pts) with <ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration.. 38:5043-5043. 2020
Early discontinuation to adjuvant endocrine therapy in the ECOG-ACRIN TAILORx Trial.. 38:7004-7004. 2020
Effect of neoadjuvant immunotherapy and targeted therapies on surgical resection in patients with solid tumors: A systematic review and meta-analysis.. 38:e16656-e16656. 2020
Impact of concurrent angiotensin inhibitors on outcomes with PD1/L1 inhibitors for patients (pts) with metastatic urothelial carcinoma (mUC).. 38:e17044-e17044. 2020
Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC).. 38:12068-12068. 2020
Locoregional recurrence following pathologic complete response in patients with T1-3 N0 breast cancer treated with neoadjuvant chemotherapy, breast conserving surgery and whole breast radiation: Is a trial of omission of radiation warranted?. 38:e12625-e12625. 2020
Outcomes of patients (pts) with metastatic urothelial carcinoma (mUC) following discontinuation of enfortumab-vedotin (EV): Emergence of a new unmet need.. 38:5048-5048. 2020
Primary analysis of a phase II study of metastasis-directed ablative therapy to PSMA (¹⁸F-DCFPyL) PET-MR/CT defined oligorecurrent prostate cancer.. 38:5553-5553. 2020
Psychosocial outcomes following surgery in women with unilateral, nonhereditary breast cancer.. 38:570-570. 2020
The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL).. 38:e20019-e20019. 2020
The impact of primary pancreatic tumor location on clinical outcomes in advanced disease: Results from the chord consortium.. 38:e19267-e19267. 2020
The impact of tobacco retail density on overall survival (OS) in lung cancer survivors.. 38:12058-12058. 2020
[OPTIMAL 3] A phase III trial to evaluate the efficacy and safety of DHP107 (Liporaxel, oral paclitaxel) compared to Taxol (IV paclitaxel) as first line therapy in patients with recurrent or metastatic HER2 negative breast cancer (BC) (NCT03315364).. 38:TPS1106-TPS1106. 2020
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. 38:1608-1632. 2020
Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial. 38:1463-1473. 2020
A comparison of combined immune checkpoint inhibitors (IO) versus vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in the treatment of advanced clear cell renal cell carcinoma.. 38:692-692. 2020
A methodological comparison of mapping algorithms to obtain health utilities derived using cross-sectional and longitudinal data: Secondary analysis of NRG/RTOG 0415.. 38:55-55. 2020
A multicenter phase II study of avelumab in patients with locally advanced or metastatic penile cancer (PC) who are unfit for, or have progressed on or after platinum-based chemotherapy: (ALPACA).. 38:TPS7-TPS7. 2020
Any regression of tumor (ART) within 12 weeks versus RECIST 1.1 response category as an intermediate endpoint to assess the activity of immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC).. 38:473-473. 2020
Conditional immune adverse event rate in urothelial and renal cell carcinoma patients treated with immune checkpoint inhibitors.. 38:481-481. 2020
Impact of histology and toxicities on outcomes of patients with muscle invasive bladder cancer receiving neoadjuvant chemotherapy.. 38:540-540. 2020
Real-world evidence of cabozantinib in metastatic renal-cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. 38:682-682. 2020
The prevalence of cardiovascular disease and its risk factors among prostate cancer patients treated with and without androgen deprivation.. 38:364-364. 2020
The relationship between socioeconomic status and treatment for prostate cancer in a universal healthcare system: A population-based analysis.. 38:361-361. 2020
Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial.. 38:276-276. 2020
SALVO: Single-arm phase II study of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.. 38:TPS65-TPS65. 2020
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. 38:496-520. 2020
Effect of neoadjuvant immunotherapy and targeted therapies on surgical resection in patients with solid tumors: A systematic review and meta-analysis.. 38:511-511. 2020
Prognostic factors associated with short-term survival (STS) in advanced pancreatic cancer (APC): A multicenter analysis from the CHORD consortium.. 38:650-650. 2020
Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. 37:2270-2290. 2019
A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration-resistant prostate cancer.. 37:11501-11501. 2019
Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs).. 37:e16038-e16038. 2019
Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiotherapy (CRT) +/- metformin in locally advanced Non-Small Cell Lung Cancer (NSCLC).. 37:8502-8502. 2019
Simultaneous resection of colorectal cancer with synchronous liver metastases: A survey-based analysis.. 37:e15073-e15073. 2019
Simultaneous versus staged resection for synchronous colorectal cancer liver metastases: A population-based cohort study.. 37:3612-3612. 2019
Tobacco retail availability and tobacco cessation in lung and head and neck (HN) cancer survivors.. 37:11559-11559. 2019
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. 37:1228-1263. 2019
Errata. 37:612-612. 2019
Preliminary results of a two stage phase II study of ¹⁸F-DCFPyL PET-MR for enabling oligometastases ablative therapy in subclinical prostate cancer.. 37:250-250. 2019
Reply to J. David et al. 37:441-441. 2019
Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S).. 37:422-422. 2019
Treatment of hepatocellular carcinoma (HCC) after sorafenib (S) over the last 10 years.. 37:438-438. 2019
National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer. 36:3259-3268. 2018
Prostate Cancer Radiotherapy: An Evolving Paradigm. 36:2909-2913. 2018
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). 36:2017-2023. 2018
Predictors of Unemployment After Breast Cancer Surgery: A Systematic Review and Meta-Analysis of Observational Studies. 36:1868-1879. 2018
A meta-analysis exploring the role of PET and PET-CT in the management of potentially resectable colorectal cancer liver metastasis.. 36:3547-3547. 2018
A real-world multicenter analysis of first (1L) and second line (2L) treatment of advanced pancreatic adenocarcinoma (APC).. 36:e16210-e16210. 2018
Association of circulating tumor (ct)-DNA genomic alterations (GA) with outcomes in metastatic urothelial carcinoma (mUC).. 36:4540-4540. 2018
Cctg BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993).. 36:4505-4505. 2018
Effect of PET-CT on disease recurrence and its management in patients with potentially resectable colorectal cancer liver metastases. The long-term results of a randomized controlled trial (PET-CT Imaging prior to liver resection for colorectal adenocarcinoma metastases).. 36:3527-3527. 2018
Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline. 36:1521-1539. 2018
Preclinical studies of BMI-1 modulator PTC596 in diffuse intrinsic pontine gliomas, pediatric high-grade gliomas and medulloblastoma.. 36:e14051-e14051. 2018
Radium-223: Disease response and fracture assessment by whole body diffusion-weighted MRI (WB-DWMRI) in metastatic castration resistant prostate cancer (mCRPC).. 36:5024-5024. 2018
Utility and prognostic value of ¹⁸F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma.. 36:8023-8023. 2018
Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. 36:1323-1329. 2018
Evaluating the impact of survivorship models on health system resources and costs.. 36:1-1. 2018
Antibiotic use and outcomes with systemic therapy in metastatic renal cell carcinoma (mRCC).. 36:607-607. 2018
Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. 36:563-571. 2018
A real world multicenter study of first (1L) and second (2L) line treatment patterns and outcomes in advanced pancreatic cancer (APC).. 36:476-476. 2018
A real-world comparison of multi-modality therapies in locally advanced gastro-esophageal junction (GEJ) cancers.. 36:96-96. 2018
Adjuvant therapy use and outcomes of stage II and III colorectal cancer (CRC): Comparison of young and elderly patients (pts) in a large, contemporary, population-based Canadian database.. 36:807-807. 2018
Effect of PET-CT on disease recurrence and its management in patients with potentially resectable colorectal cancer liver metastases: The long-term results of a randomized control trial.. 36:562-562. 2018
Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S).. 36:248-248. 2018
Systematic review and meta-analysis of the effect of pre-operative PET/PET-CT in the management of patients with potentially resectable colorectal cancer liver metastasis.. 36:591-591. 2018
Population-Based Study to Determine the Health System Costs of Using the 21-Gene Assay. 36:238-243. 2018
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update. 35:3978-3986. 2017
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. 35:3484-3515. 2017
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. 35:3097-3104. 2017
Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. 35:2960-2974. 2017
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. 35:2934-2941. 2017
Reply to J.A. Vargo et al, H.J.A. Adams et al, E. Hindié et al, and S. Kothari et al. 35:2854-2855. 2017
Reply to T.J. Powles et al. 35:2720-2721. 2017
Patient-Reported Outcomes 1 Year After Immediate Breast Reconstruction: Results of the Mastectomy Reconstruction Outcomes Consortium Study. 35:2499-2506. 2017
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. 35:2062-2081. 2017
Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. 35:1884-1890. 2017
Limited-Stage Hodgkin Lymphoma: Clarifying Uncertainty. 35:1760-1763. 2017
A randomized phase II/III study comparing stereotactic body radiotherapy (SBRT) versus conventional palliative radiotherapy (CRT) for patients with spinal metastases (NCT02512965).. 35:TPS10129-TPS10129. 2017
Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression.. 35:4573-4573. 2017
Effect of sorafenib (S) starting dose and dose intensity on survival in patients with hepatocellular carcinoma (HCC): Results from a Canadian multicenter HCC database.. 35:4084-4084. 2017
Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. 35:1641-1649. 2017
Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer (NSCLC).. 35:9024-9024. 2017
Outcomes of women with small, early-stage breast cancer in Manitoba from 2006-2011.. 35:e12000-e12000. 2017
Patterns of unavoidable and potentially avoidable hospitalizations among cancer patients.. 35:e18030-e18030. 2017
Prevalence of oligoprogressive, metastatic castration-resistant prostate cancer (mCRPC) amenable to stereotactic ablative radiotherapy (SABR) in men undergoing abiraterone acetate (AA) therapy.. 35:e16509-e16509. 2017
Primary care vs. oncology-driven surveillance following adjuvant chemotherapy in resected pancreas cancer.. 35:e18163-e18163. 2017
Reply to L.B. Marks et al. 35:1258-1259. 2017
An evaluation of the breast cancer Well Follow-up Care Initiative using administrative databases: A new model of analysis.. 35:1-1. 2017
Clinical trials in Ontario’s quality-based funding model.. 35:186-186. 2017
Circulating tumor (ct)-DNA alterations in advanced urothelial carcinoma: Association with outcomes and evolution with therapy.. 35:334-334. 2017
Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy.. 35:149-149. 2017
Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. 35:668-680. 2017
Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival.. 35:346-346. 2017
Prevalence of oligoprogressive, metastatic castration-resistant prostate cancer (mCRPC) amenable to stereotactic ablative radiotherapy (SABR) in men undergoing abiraterone acetate (AA) therapy.. 35:e587-e587. 2017
Proton pump inhibitors (PPIs) and survival outcomes in patients with metastatic renal cell carcinoma (mRCC).. 35:493-493. 2017
Incidence of venous thromboembolic events following major pelvic and abdominal surgery for cancer.. 35:478-478. 2017
Methylomic classifiers of anal cancer outcomes: An NRG Oncology / RTOG 98-11 tissue study.. 35:588-588. 2017
Primary care vs. oncology-driven surveillance following adjuvant chemotherapy in resected pancreas cancer.. 35:421-421. 2017
Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. 34:4431-4442. 2016
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. 34:4345-4353. 2016
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. 34:3914-3920. 2016
Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. 34:3537-3543. 2016
Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer. 34:2980-2987. 2016
Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer. 34:2969-2979. 2016
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. 34:2325-2332. 2016
A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.. 34:LBA1-LBA1. 2016
Patient-reported outcomes from MA.17R: A randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.. 34:LBA506-LBA506. 2016
Eight Cycles of ABVD Versus Four Cycles of BEACOPP_escalatedPlus Four Cycles of BEACOPP_baselinein Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. 34:2028-2036. 2016
A Randomized Phase II study of Reolysin in Patients with Previously Treated Advanced or Metatstatic Non Small Cell Lung Cancer (NSCLC) receiving Standard Salvage Chemotherapy – Canadian Cancer Trials Group IND 211.. 34:e20512-e20512. 2016
A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677).. 34:LBA2-LBA2. 2016
A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.. 34:LBA1-LBA1. 2016
IND.210: A randomized phase 2 trial of FOLFOX6/bevacizumab with or without reovirus (Reo) in patients (pts) with metastatic colorectal cancer (mCRC).. 34:3546-3546. 2016
Patient-reported outcomes from MA.17R: A randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.. 34:LBA506-LBA506. 2016
Pointed Progress in Second-Line Advanced Non–Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. 34:1676-1688. 2016
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. 34:1500-1509. 2016
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. 57:23-30. 2016
Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario. 34:1065-1071. 2016
Assessing the quality of chemotherapy in an episode-based funding model in Ontario.. 34:2-2. 2016
Use of alkylating chemotherapy in high-grade neuroendocrine tumours: Evaluation of real-world data.. 34:78-78. 2016
Effects of adjuvant 5FU/oxaliplatin chemotherapy in individuals treated for colon cancer on cognitive and mobility function.. 34:750-750. 2016
PET-CT compared to no PET-CT in the management of potentially resectable colorectal cancer liver metastases: The costs implications of a randomized controlled trial.. 34:296-296. 2016
Radiation of the Internal Mammary Nodes: Is There a Benefit?. 34:297-299. 2016
Systemic treatment patterns in small bowel and appendiceal adenocarcinomas (SBA and AA): A population-based study.. 34:242-242. 2016
Regular aspirin use and the risk of lethal prostate cancer in the Physicians' Health Study.. 34:306-306. 2016
The impact of histological variants on bladder cancer survival: A population-based analysis.. 34:458-458. 2016
Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes. 34:69-75. 2016
Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study. 33:4085-4092. 2015
Reply to L. Wiener et al. 33:3975-3975. 2015
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. 33:3488-3515. 2015
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of highly or moderately emetogenic chemotherapy (HEC, MEC).. 33:210-210. 2015
Toward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge. 33:3065-3073. 2015
Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme. 33:2296-2302. 2015
Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy. 33:2035-2040. 2015
A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma.. 33:TPS9089-TPS9089. 2015
A systematic approach to smoking cessation in Ontario’s Regional Cancer Programs.. 33:6544-6544. 2015
Cancer-related cognitive dysfunction (CRCD) and psychosocial development in young adult cancer survivors.. 33:TPS9636-TPS9636. 2015
Cardiovascular events in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors: A systematic review and meta-analysis.. 33:7056-7056. 2015
Cochrane systematic review and meta-analysis of adjuvant therapy for stage II colon cancer.. 33:3513-3513. 2015
Expression of thyroid hormone receptor alpha (THRα) isoforms in triple negative breast cancer (TNBC).. 33:e12082-e12082. 2015
Impact of rolapitant on quality of life (QoL) in patients (pts) receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC).. 33:9615-9615. 2015
Improving fitness after childhood cancer: A novel exercise clinic for pediatric oncology patients.. 33:e21030-e21030. 2015
Physicians’ attitudes toward systematic symptom assessment and management: Results from all regional cancer centres in Ontario (Canada).. 33:e17678-e17678. 2015
Quality of care provided to prostate cancer patients for prevention and treatment of osteoporosis induced by androgen deprivation therapy: Results of a chart audit.. 33:e16074-e16074. 2015
Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity.. 33:533-533. 2015
Survival benefit of tumor treating fields plus stereotactic radiosurgery for recurrent malignant gliomas.. 33:e13036-e13036. 2015
Trends in demographics, incidence, and survival in children, adolescents and young adults (AYA) with melanoma: A Surveillance, Epidemiology and End Results (SEER) population-based analysis.. 33:9058-9058. 2015
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. 33:1574-1583. 2015
High-dose interleukin-2 (HD IL-2) for metastatic renal Cell carcinoma (mRCC): Contemporary utilization trends in the United States.. 33:449-449. 2015
Trends in utilization, perioperative outcomes, and costs among open, laparoscopic, and robotic nephroureterectomies: A 10-year population-based analysis.. 33:337-337. 2015
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. 33:654-656. 2015
Bronchoalveolar Lavage and Lung Biopsy in Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: A Systematic Review and Meta-Analysis. 33:501-509. 2015
Duration of Androgen Suppression Before Radiotherapy for Localized Prostate Cancer: Radiation Therapy Oncology Group Randomized Clinical Trial 9910. 33:332-339. 2015
Diagnostic Criteria for the Classification of Cancer-Associated Weight Loss. 33:90-99. 2015
Impact of Reirradiation of Painful Osseous Metastases on Quality of Life and Function: A Secondary Analysis of the NCIC CTG SC.20 Randomized Trial. 32:3867-3873. 2014
Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial. 32:3810-3816. 2014
How Long to Treat Acute Venous Thrombosis in Cancer: Can Treatment Be Personalized?. 32:3586-3587. 2014
Integration of system-level patient-reported outcome measurement into everyday clinical care: Lessons learned from the cancer care Ontario experience.. 32:159-159. 2014
Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. 32:3490-3496. 2014
A new model of care: An advanced practice radiation therapy role.. 32:131-131. 2014
Identifying targets for outpatient palliative care wait times in Ontario.. 32:258-258. 2014
Measuring alignment with evidence-informed practice in Ontario’s systemic treatment funding model.. 32:15-15. 2014
Population-based standardized symptom screening: Cancer Care Ontario’s Edmonton Symptom Assessment System and performance status initiatives.. 32:56-56. 2014
Quality indicators of end-of-life cancer care: What rate is right?. 32:57-57. 2014
Reporting on quality indicators in renal cell carcinoma: Proportion of metastatic patients who initially commence on full-dose targeted therapy.. 32:265-265. 2014
Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. 32:3436-3448. 2014
Transition of breast cancer (BC) survivors to primary care: Results of a Cancer Care Ontario (CCO) pilot project.. 32:58-58. 2014
Twenty-Twenty Hindsight: An Adjuvant Breast Cancer Trial Through the Retrospectoscope. 32:2284-2286. 2014
Randomized Trial of a Telephone-Based Weight Loss Intervention in Postmenopausal Women With Breast Cancer Receiving Letrozole: The LISA Trial. 32:2231-2239. 2014
Reply to J. Menczer. 32:2114-2114. 2014
Treatment Delay in Endometrial Cancer. 32:2113-2114. 2014
Assessment of a dyspnea clinic for patients with thoracic malignancies.. 32:e20667-e20667. 2014
Interobserver variation in predicting fracture risk in patients with long bone metastatic lesions.. 32:e20524-e20524. 2014
LEGEND: A randomised phase II study comparing lenalidomide plus rituximab, gemcitabine, and methylprednisolone (R-GEM-L) to rituximab, gemcitabine, methylprednisolone, and cisplatin (R-GEM-P) in second-line treatment of diffuse large B-cell lymphoma (DLBCL).. 32:TPS8618-TPS8618. 2014
PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT).. 32:4022-4022. 2014
Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.. 32:5051-5051. 2014
Limited-Stage Hodgkin Lymphoma: Managing Uncertainty. 32:1180-1182. 2014
Cost Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients With Advanced ALK-Positive Non–Small-Cell Lung Cancer. 32:1012-1019. 2014
Cytogenetic Prognostication Within Medulloblastoma Subgroups. 32:886-896. 2014
Results of a phase II trial of abiraterone acetate (AA) combined with dutasteride (DUT) for men with metastatic castration resistant prostate cancer (mCRPC).. 32:126-126. 2014
Are the cardiovascular side effects of bevacizumab caused by autonomic nervous system toxicity?. 32:429-429. 2014
Effect of dose intensification (DI) of octreotide-LAR (O-LAR) among symptomatic patients with neuroendocrine tumors (NETs).. 32:299-299. 2014
Impact of Wait Times on Survival for Women With Uterine Cancer. 32:27-33. 2014
Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non–Small-Cell Lung Cancer: ECOG 5597. 31:4179-4187. 2013
Interim Cosmetic and Toxicity Results From RAPID: A Randomized Trial of Accelerated Partial Breast Irradiation Using Three-Dimensional Conformal External Beam Radiation Therapy. 31:4038-4045. 2013
Randomized Trial of Decongestive Lymphatic Therapy for the Treatment of Lymphedema in Women With Breast Cancer. 31:3758-3763. 2013
Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. 31:3182-3190. 2013
Reply to C.M. Booth et al. 31:3300-3300. 2013
Selective Application of a Test Based on Risk: Using Limited Resources Wisely. 31:2847-2848. 2013
Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. 31:2927-2935. 2013
Surrogacy of Financial Conflicts of Interest. 31:2645-2647. 2013
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. 31:2189-2204. 2013
A multicenter phase II study of bevacizumab (B) and temsirolimus (T) in women with recurrent epithelial ovarian cancer (OC): A study of the Mayo, Chicago, California, New York, Southeast, and Princess Margaret Phase II Consortia.. 31:5517-5517. 2013
A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21).. 31:TPS3647-TPS3647. 2013
A randomized trial of single versus multiple fractions (Fx) for re-irradiation (RE-RT) of painful bone metastases (PBM): NCIC CTG SC.20.. 31:9502-9502. 2013
Bowel obstruction with stage IV cancer: The benefit of introduction of formal palliative care service.. 31:e20573-e20573. 2013
Canadian ALK (CALK): A pan-Canadian multicenter study to optimize and standardize ALK immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for ALK gene rearrangements.. 31:8096-8096. 2013
Cancer Care Ontario’s lung disease pathway initiative: Building resources for lung cancer quality care.. 31:e17531-e17531. 2013
Characteristics of clinical trials for adolescent and young adult (AYA) cancer patients (pts) in Ontario.. 31:e17525-e17525. 2013
Clinical impact of EGFR mutation fraction and tumor cellularity in EGFR mutation positive NSCLC.. 31:e19077-e19077. 2013
Cochrane systematic review and meta-analysis of adjuvant chemotherapy for stage II colon cancer.. 31:3548-3548. 2013
Competing risks of death in NCIC CTG MA.27 adjuvant exemestane versus anastrozole.. 31:564-564. 2013
Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC).. 31:1033-1033. 2013
Effective routine electronic symptom screening and use of evidence to improve cancer symptom management in Ontario, Canada.. 31:e20507-e20507. 2013
Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM).. 31:9032-9032. 2013
Final results of a phase I study evaluating the combination of linsitinib, a dual inhibitor of insulin-like growth factor-1 receptor (IGF-1R), and insulin receptor (IR) with weekly paclitaxel (PAC) in patients (Pts) with advanced solid tumors.. 31:e13502-e13502. 2013
First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.. 31:2505-2505. 2013
Impact of response to prior chemotherapy (RTPC) on outcomes in second-line therapy for advanced urothelial carcinoma (UC): Implications for trial design.. 31:4539-4539. 2013
Impact of wait times on survival of women with uterine cancer.. 31:5586-5586. 2013
Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC).. 31:4524-4524. 2013
Perioperative epidural analgesia and recurrence-free survival for ovarian cancer surgery: A retrospective analysis.. 31:e16534-e16534. 2013
Phase I trial of trebananib (AMG 386) plus temsirolimus (Tr + T) in patients (pts) with advanced solid tumors (PJC-008/NCI#9041).. 31:2534-2534. 2013
Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study—NCT00811369.. 31:574-574. 2013
Real-time clinical application of next-generation sequencing (NGS): Results from a multicenter program.. 31:11016-11016. 2013
Results from a structured interprofessional palliative care rehabilitation program in oncology.. 31:e20598-e20598. 2013
Risk and predictors of suicide in colorectal cancer patients: A SEER analysis.. 31:9596-9596. 2013
Simulating the cost-effectiveness of lung cancer screening by low-dose CT scan in Canada.. 31:6550-6550. 2013
The effect of surgery type on survival and recurrence in very young women with breast cancer.. 31:1002-1002. 2013
The role of FSH in castration-induced adipogenesis: Highlighting differences between orchiectomy, GNRH agonists, and antagonists.. 31:e16011-e16011. 2013
Toward integration of palliative care into cancer care: A study on profile of psychosocial and clinical complications among attendees of a Nigerian oncological center.. 31:e20675-e20675. 2013
Weekly vinblastine in chemotherapy-naive children with unresectable or progressive low grade glioma: A Canadian cooperative study.. 31:10029-10029. 2013
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial. 31:1398-1404. 2013
Central Venous Catheter Care for the Patient With Cancer: American Society of Clinical Oncology Clinical Practice Guideline. 31:1357-1370. 2013
Autologous and Allogeneic Stem-Cell Transplantation for Transformed Follicular Lymphoma: A Report of the Canadian Blood and Marrow Transplant Group. 31:1164-1171. 2013
Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. 31:1202-1210. 2013
Comparative Effectiveness Research Paradigm: Implications for Systematic Reviews and Clinical Practice Guidelines. 30:4202-4207. 2012
Comparative Effectiveness Research in Oncology: An Overview. 30:4181-4184. 2012
Epilogue: The Peril and the Promise of Comparative Effectiveness Research in Oncology. 30:4282-4282. 2012
Using a disease pathway management (DPM) approach to improve the quality of lung cancer care in Ontario.. 30:93-93. 2012
Policy Directives in Cancer, Organizational Responses, and the Need for Evaluation. 30:3907-3908. 2012
Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study. 30:3396-3401. 2012
Hepatitis B, Rituximab, Screening, and Prophylaxis: Effectiveness and Cost Effectiveness. 30:3155-3157. 2012
The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs. 30:3012-3019. 2012
Randomized Controlled Trial of a Computerized Decision Aid on Adjuvant Radioactive Iodine Treatment for Patients With Early-Stage Papillary Thyroid Cancer. 30:2906-2911. 2012
High Incidence of Vertebral Fractures in Children With Acute Lymphoblastic Leukemia 12 Months After the Initiation of Therapy. 30:2760-2767. 2012
Method to Our Madness or Madness in Our Methods? Pitfalls in Trial Methodology. 30:2025-2027. 2012
A phase II study of RO4929097 (RO), a gamma-secretase inhibitor, in advanced platinum (Pt)-resistant (R) ovarian cancer (OC): A study of the PMH, Chicago, and California phase II consortia.. 30:5019-5019. 2012
A phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6).. 30:TPS5600-TPS5600. 2012
A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29.. 30:7511-7511. 2012
Cognitive function and fatigue in colorectal cancer (CRC) patients: A prospective longitudinal controlled study.. 30:9021-9021. 2012
Do patient-reported symptoms predict for emergency department visits? A population-based analysis.. 30:6039-6039. 2012
Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. 30:4569-4569. 2012
Feasibility and acceptability of patient-reported outcomes data collection for clinical care following breast reconstruction.. 30:9042-9042. 2012
Impact of concurrent (CON) and sequential (SEQ) radiotherapy (RT) with adjuvant aromatase inhibitors (AI) in early-stage breast cancer (EBC): NCIC CTG MA.27.. 30:500-500. 2012
Insurance status and cancer disparities in adolescents and young adults age 15 to 39: National Cancer Data Base, 1998-2003.. 30:6011-6011. 2012
MicroRNA signature to predict sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC).. 30:3521-3521. 2012
NCIC IND.190: A phase I trial of MK-0646 in combination with cisplatin and etoposide in extensive-stage small cell lung cancer (ES SCLC).. 30:7093-7093. 2012
Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.. 30:5001-5001. 2012
Oncology education in Canadian undergraduate and postgraduate medical programs: A survey of educators and learners.. 30:e16558-e16558. 2012
Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919.. 30:LBA671-LBA671. 2012
Patient-reported cognitive impairments among women with breast cancer randomly assigned to hormonal therapy (HT) alone versus chemotherapy followed by hormonal therapy (C+HT): Results from the Trial Assigning Individualized Options for Treatment (TAILORx).. 30:9020-9020. 2012
Patient-reported satisfaction with reconstructed breasts in the long-term survivorship period: Comparison of autologous and nonautologous breast reconstruction.. 30:9043-9043. 2012
Phase II Study of Ganitumab, a Fully Human Anti–Type-1 Insulin-Like Growth Factor Receptor Antibody, in Patients With Metastatic Ewing Family Tumors or Desmoplastic Small Round Cell Tumors. 30:1849-1856. 2012
Positron emission tomography/computed tomography (PET/CT) for the diagnosis of recurrent cancer (PETREC): A multicenter, prospective cohort study.. 30:6049-6049. 2012
Pretreatment neurocognitive function (NCF) status in head and neck cancer (HNC) patients (pts) with comparison to control cohort.. 30:5587-5587. 2012
Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial.. 30:4644-4644. 2012
Quantitative immunohistochemical (IHC) assessment of ataxia-telangiectasia mutated (ATM) in estrogen receptor (ER) negative early breast cancer (BC).. 30:e21083-e21083. 2012
Results of a cluster randomized trial to evaluate a nursing lead supportive care intervention in newly diagnosed breast and colorectal cancer patients.. 30:6035-6035. 2012
Stage III NSCLC: How many patients are really suitable for radical treatment approaches?. 30:e17532-e17532. 2012
The morbidity of cytoreduction/hyperthermic intraperitoneal chemoperfusion (HIPEC) in the modern era.. 30:e14172-e14172. 2012
The value of personalizing medicine: Medical oncologists’ and patients’ perspectives on genomic testing of breast tumors in chemotherapy treatment decisions.. 30:e11000-e11000. 2012
Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy.. 30:4522-4522. 2012
Utility of the Edmonton Frail Scale (EFS) in identifying frail elderly patients during treatment of colorectal cancer (CRC).. 30:e14001-e14001. 2012
Is Colon Cancer Survival Influenced by Tumor Location?. 30:1732-1733. 2012
Funding Oncology Clinical Trials: Are Cooperative Group Trials Sustainable?. 30:1456-1461. 2012
Screening for Osteoporosis in Postmenopausal Women With Breast Cancer Receiving Aromatase Inhibitors: Less Is More?. 30:1408-1410. 2012
Prospective Study of 2-[¹⁸F]Fluorodeoxyglucose Positron Emission Tomography in the Assessment of Regional Nodal Spread of Disease in Patients With Breast Cancer: An Ontario Clinical Oncology Group Study. 30:1274-1279. 2012
Reply to M. Jefford et al and C.T. Stricker et al. 30:1393-1394. 2012
Cohort Study of Somatostatin-Based Radiopeptide Therapy With [⁹⁰Y-DOTA]-TOC Versus [⁹⁰Y-DOTA]-TOC Plus [¹⁷⁷Lu-DOTA]-TOC in Neuroendocrine Cancers. 30:1100-1106. 2012
Opioid Prescription After Pain Assessment: A Population-Based Cohort of Elderly Patients With Cancer. 30:1095-1099. 2012
Consistency in the Analysis and Reporting of Primary End Points in Oncology Randomized Controlled Trials From Registration to Publication: A Systematic Review. 30:210-216. 2012
Evolution of Clinical Trials Registries. 30:131-133. 2012
Molecular Detection of Tumor Cells in Regional Lymph Nodes Is Associated With Disease Recurrence and Poor Survival in Node-Negative Colorectal Cancer: A Systematic Review and Meta-Analysis. 30:60-70. 2012
Evaluating Survivorship Care Plans: Results of a Randomized, Clinical Trial of Patients With Breast Cancer. 29:4755-4762. 2011
Perspectives of Patients on the Utility of Electronic Patient-Reported Outcomes on Cancer Care. 29:4213-4214. 2011
Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14. 29:3869-3876. 2011
Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group. 29:3396-3401. 2011
Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group. 29:3278-3285. 2011
Reply to J.-J. de Arriba, et al. 29:2833-2834. 2011
NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer.. 29:LBA1003-LBA1003. 2011
Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [⁹⁰Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers. 29:2416-2423. 2011
An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma metastases (CAM).. 29:3520-3520. 2011
An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival.. 29:7018-7018. 2011
Frequency of fertility discussions among young patients diagnosed with colorectal cancer.. 29:e19735-e19735. 2011
Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC).. 29:4031-4031. 2011
NCIC CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer.. 29:LBA1003-LBA1003. 2011
Neurocognitive function (NCF) in patients (pts) treated with chemo/bio-radiotherapy (C/B-RT) for head and neck cancers (HNC).. 29:5522-5522. 2011
Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. 29. 2011
Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL).. 29:8001-8001. 2011
Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors.. 29:9005-9005. 2011
Results of an Ontario Clinical Oncology Group (OCOG) prospective cohort study on the use of FDG PET/CT to predict the need for neck dissection following radiation therapy of head and neck cancer (HNC).. 29:5504-5504. 2011
Trajectory of Performance Status and Symptom Scores for Patients With Cancer During the Last Six Months of Life. 29:1151-1158. 2011
Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non–Small-Cell Lung Cancer. 29:1075-1082. 2011
Cardiac Troponin Cutoffs: The Importance of Assay Sensitivity and the Patient Population. 29:e177-e177. 2011
Initial report of RTOG 9601, a phase III trial in prostate cancer: Effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3,N0 disease and elevated PSA levels.. 29:1-1. 2011
Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts)with metastatic castration-resistant prostate cancer (mCRPC). 29. 2011
Results of a phase II study of single-agent nab-paclitaxel in platinum-refractory second-line metastatic urothelial carcinoma (UC).. 29:241-241. 2011
Multicenter, Randomized, Cross-Over Clinical Trial of Venlafaxine Versus Gabapentin for the Management of Hot Flashes in Breast Cancer Survivors. 28:5147-5152. 2010
Case Report: Celiac Disease Masquerading As Bone Metastasis in a 29-Year-Old Woman. 28:e623-e625. 2010
Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors. 28:4674-4682. 2010
Reply to D.J. Stewart. 28:e651-e651. 2010
Continental Divide? The Attitudes of US and Canadian Oncologists on the Costs, Cost-Effectiveness, and Health Policies Associated With New Cancer Drugs. 28:4149-4153. 2010
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer. 28:3219-3226. 2010
A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC).. 28:CRA7004-CRA7004. 2010
Reply to C.D. Atkins. 28:e264-e264. 2010
A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia.. 28:5038-5038. 2010
A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC).. 28:CRA7004-CRA7004. 2010
Randomized Phase II Trials: Inevitable or Inadvisable?. 28:2641-2647. 2010
Conventional and Complementary Therapies: A Tale of Two Research Standards?. 28:1979-1981. 2010
Generalizing the Results of Cancer Clinical Trials. 28:187-189. 2010
Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer. 28:77-82. 2010
Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study. 28:49-55. 2010
Evidence-Based Approach to the Introduction of Positron Emission Tomography in Ontario, Canada. 27:5607-5613. 2009
Improving Cancer Outcomes Through International Collaboration in Academic Cancer Treatment Trials. 27:5109-5114. 2009
New Antithrombotic Drugs: Potential for Use in Oncology. 27:4912-4918. 2009
Prevention of Thrombosis in Ambulatory Patients With Cancer. 27:4885-4888. 2009
Presentation of Nonfinal Results of Randomized Controlled Trials at Major Oncology Meetings. 27:3938-3944. 2009
Safety and Efficacy of Patupilone in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer: A Phase I, Open-Label, Dose-Escalation Study. 27:3097-3103. 2009
A phase II study evaluating the safety and efficacy of patupilone in patients with platinum refractory/resistant ovarian, primary fallopian, or peritoneal cancer. 27:5563-5563. 2009
A phase II study of aflibercept (VEGF trap) in recurrent or metastatic gynecologic soft-tissue sarcomas: A study of the Princess Margaret Hospital Phase II Consortium. 27:5591-5591. 2009
A phase II study of single agent abraxane as second-line therapy in patients with advanced urothelial carcinoma. 27:e16058-e16058. 2009
A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the PMH Phase II Consortium. 27:5576-5576. 2009
A phase II trial of voreloxin in women with platinum-resistant ovarian cancer. 27:5559-5559. 2009
A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer. 27:e20514-e20514. 2009
Comparison of randomized phase II studies (RP2s) and subsequent randomized controlled studies (RCTs) using identical systemic therapies. 27:e17515-e17515. 2009
Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: A phase II randomized study. 27:e16529-e16529. 2009
Economic guidelines for oncology products: Adaptation of the Canadian Agency for Drugs and Technologies in Health (CADTH) technology assessment guidance document. 27:e17572-e17572. 2009
Hypertension (HTN) in National Cancer Institute of Canada Clinical Trials Group study BR.24: A randomized, double-blind phase II trial of carboplatin (C) and paclitaxel (P) with either daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo, in patients with advanced non-small cell lung cancer. 27:3527-3527. 2009
Impact of positron emission tomography (PET) in stage III non-small cell lung cancer (NSCLC): A prospective randomized trial (PET START). 27:7548-7548. 2009
Integration between primary care providers and the cancer system: Gaps and opportunities. 27:6584-6584. 2009
PET-CT compared to invasive mediastinal staging in non-small cell lung cancer (NSCLC). 27:7575-7575. 2009
Phase I study of temsirolimus (CCI-779), carboplatin, and paclitaxel in patients (pts) with advanced solid tumors: NCIC CTG IND 179. 27:3558-3558. 2009
Phase II study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer. 27:5577-5577. 2009
Predictors of recurrent thrombosis and anticoagulant-related bleeding in patients with cancer. 27:9565-9565. 2009
Primary tumor and patient characteristics in breast cancer as predictors of adjuvant chemotherapy regimen: A regression model. 27:e11632-e11632. 2009
The McGill Cancer Nutrition and Rehabilitation Program. 27:9623-9623. 2009
The management of dysphagia in esophageal cancer patients undergoing neoadjuvant chemotherapy: Is invasive tube feeding required?. 27:9613-9613. 2009
Trends in the application of dynamic allocation methods in multiarm cancer clinical trials. 27:6550-6550. 2009
Two-years biochemical failure-free survival following high intensity focused ultrasound (HIFU) for localized prostate cancer: Prospective single center study of 196 patients. 27:5117-5117. 2009
Willingness of breast cancer survivors to participate in a randomized controlled trial (RCT) of digital mammography with or without magnetic resonance imaging (MRI) as breast cancer (BC) surveillance: A feasiblity study. 27:1534-1534. 2009
Are Cancer-Related Decision Aids Effective? A Systematic Review and Meta-Analysis. 27:974-985. 2009
In Reply. 27:647-647. 2009
Randomized, Double-Blind, Placebo-Controlled Trial of Epoetin Alfa in Men With Castration-Resistant Prostate Cancer and Anemia. 27:644-646. 2009
Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer. 27:404-410. 2009
Impact of Caring for a Child With Cancer on Parents’ Health-Related Quality of Life. 26:5884-5889. 2008
Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer. 26:5465-5476. 2008
Registries That Show Efficacy: Good, but Not Good Enough. 26:5316-5319. 2008
Identification of Cancer Care and Protocol Characteristics Associated With Recruitment in Breast Cancer Clinical Trials. 26:4458-4465. 2008
Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148. 26:4319-4325. 2008
Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. 26:4268-4275. 2008
Phase II Stopping Rules That Employ Response Rates and Early Progression. 26:3715-3720. 2008
Dual-Agent Molecular Targeting of the ErbB2 Receptor: Killing One Bird With Two Stones. 26:3301-3302. 2008
In Reply. 26:2788-2788. 2008
Stopping Trials for Benefit Can (Sometimes) Benefit Patients. 26:2787-2788. 2008
A prospective economic analysis of cost-effectiveness of cetuximab for metastatic colorectal cancer patients from the NCIC CTG and AGITG CO.17 trial. 26:6528-6528. 2008
Final results of the Sunbelt Melanoma Trial. 26:9003-9003. 2008
Interim safety analysis of a phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC). 26:19091-19091. 2008
NCIC-CTG MA14 Trial: Tamoxifen (tam) vs. tam + octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast cancer. 26:532-532. 2008
Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial. 26:1965-1971. 2008
Efficacy, Toxicity, and Quality of Life in Older Women With Early-Stage Breast Cancer Treated With Letrozole or Placebo After 5 Years of Tamoxifen: NCIC CTG Intergroup Trial MA.17. 26:1956-1964. 2008
Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group. 26:1871-1878. 2008
Ontario Cancer Research Ethics Board: Lessons Learned From Developing a Multicenter Regional Institutional Review Board. 26:1479-1482. 2008
Nomograms to Predict Serious Adverse Events in Phase II Clinical Trials of Molecularly Targeted Agents. 26:1324-1330. 2008
Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane. 26:1106-1111. 2008
Is There a Role for Positron Emission Tomography in Breast Cancer Staging?. 26:712-720. 2008
Preface to Second Review Issue on Breast Cancer. 26:695-695. 2008
Statement of the Science Concerning Locoregional Treatments After Preoperative Chemotherapy for Breast Cancer: A National Cancer Institute Conference. 26:791-797. 2008
Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study. 26:242-245. 2008
Randomized Trial of High-Dose Chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared With Standard-Dose Chemotherapy in Women With Metastatic Breast Cancer: NCIC MA.16. 26:37-43. 2008
Randomized Trials in Oncology Stopped Early for Benefit. 26:18-19. 2008
In Reply. 25:5667-5667. 2007
American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. 25:5490-5505. 2007
Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non–Small-Cell Lung Cancer Guideline. 25:5506-5518. 2007
Neuropsychological Outcomes From a Randomized Trial of Triple Intrathecal Chemotherapy Compared With 18 Gy Cranial Radiation As CNS Treatment in Acute Lymphoblastic Leukemia: Findings From Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. 25:4914-4921. 2007
High Interleukin-15 Expression Characterizes Childhood Acute Lymphoblastic Leukemia With Involvement of the CNS. 25:4813-4820. 2007
Incidence of Metastatic Nonseminomatous Germ Cell Tumor Outside the Boundaries of a Modified Postchemotherapy Retroperitoneal Lymph Node Dissection. 25:4365-4369. 2007
Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. 25:4278-4284. 2007
Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands. 25:3978-3984. 2007
A 10-year history of lung cancer practice guideline development: Process, productivity and impact. 25:17044-17044. 2007
A multi-centre, open-label study to assess the safety of Stimuvax (BLP25 liposome vaccine or L-BLP25) in non-small cell lung cancer (NSCLC) patients (pts) with unresectable stage III disease. 25:3075-3075. 2007
A phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors. 25:3576-3576. 2007
A phase III adjuvant trial of sequenced EC + filgrastim + epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA.21). 25:550-550. 2007
A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non- small cell lung cancer (NSCLC) (NCI T99–0046, RTOG 02–70, MDA 99–303). 25:7527-7527. 2007
A randomized trial of computer and pamphlet-based versions of the Decision Board (DB). 25:6508-6508. 2007
A review of 565 phase II trial abstracts from ASCO 2005: Design characteristics of contemporary trials evaluating cytotoxic versus non-cytotoxic regimens. 25:6569-6569. 2007
A single agent, phase I pharmacodynamic study of nimotuzumab (TheraCIM-h-R3) in patients with advanced refractory solid tumors. 25:14030-14030. 2007
A tool for assessing adverse events in phase I/II oncology clinical trials. 25:6518-6518. 2007
Adherence to surveillance guidelines following curative resection for stage II and III colorectal cancer. 25:4051-4051. 2007
CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib—A trial of the PMH Phase II Consortium. 25:5519-5519. 2007
Changes in estrogen receptor (ER), progesterone receptor (PR) and HER2/neu status with time: Discordance rates between primary and metastatic breast pathology samples. 25:1024-1024. 2007
Cognitive function and fatigue in cancer patients after chemotherapy: A longitudinal cohort study in patients with colorectal cancer (CRC). 25:9099-9099. 2007
Correlation between changes in 2- or 3-year disease-free survival (DFS) and 5-year overall survival (OS) in adjuvant breast cancer trials from 1966–2006. 25:581-581. 2007
Cytokine levels in patients (pts) with colorectal cancer and breast cancer and their relationship to fatigue and cognitive function. 25:9070-9070. 2007
Descriptive study on the lost productivity in breast cancer patients. 25:6542-6542. 2007
Determining knowledge transfer gaps in the life cycle of evidence for chemotherapy in non-small cell lung cancer (NSCLC) through cumulative meta-analysis. 25:6555-6555. 2007
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival of the TAX 327 study. 25:5005-5005. 2007
Identification of cancer care and protocol characteristics associated with recruitment rate in breast cancer clinical trials in Ontario. 25:17042-17042. 2007
Initial versus recent outcomes with a non–risk adapted surveillance policy in stage I non-seminomatous germ cell tumors (NSGCT). 25:5021-5021. 2007
Lack of effect of prophylactic hematopoeitic colony stimulating factors in cancer patients and stem cell transplant recipients on short term survival: A meta-analysis of randomized trials. 25:6605-6605. 2007
Mechanisms of bone metastasis (BM) growth in patients with metastatic breast cancer (MBC): An exploratory study. 25:1102-1102. 2007
Nomograms to predict serious adverse events (SAEs) in patients (pts) enrolled in phase II clinical trials of molecularly targeted agents (MTAs). 25:6601-6601. 2007
PRODIGE: A phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. 25:2011-2011. 2007
Phase II stopping rules employing response rates and early progression. 25:2553-2553. 2007
Prospective study of specialist oncology community nursing resulting in improvements in key patient supportive care outcomes. 25:9107-9107. 2007
Randomized phase II study of maintenance vandetanib (ZD6474) in small cell lung cancer (SCLC) patients who have a complete or partial response to induction therapy: NCIC CTG BR.20. 25:7522-7522. 2007
Reliability of data collection for the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multi-center outcomes database: A methodological approach. 25:6525-6525. 2007
Screening cancer patients for clinical trial eligibility: A randomized study. 25:6529-6529. 2007
Tamoxifen (T) compared to placebo (P), after adjuvant chemotherapy (CT), in premenopausal women with early breast cancer (EBC): Interim results of NCIC-CTG MA.12. 25:547-547. 2007
The quality of phase I trial (P1T) abstracts submitted to ASCO meetings. 25:6532-6532. 2007
What can physicians do to promote patient involvement in decision making (DM) in the oncology consultation?. 25:19553-19553. 2007
Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non–Small-Cell Lung Cancer—A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group. 25:2256-2261. 2007
Predictive and Pharmacodynamic Biomarker Studies in Tumor and Skin Tissue Samples of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Erlotinib. 25:2184-2190. 2007
Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group. 25:1570-1575. 2007
Long-Term Clinical Outcome After Postchemotherapy Retroperitoneal Lymph Node Dissection in Men With Residual Teratoma. 25:1033-1037. 2007
Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Non–Small-Cell Lung Cancer With Disease-Related Anemia. 25:1027-1032. 2007
Economic Evaluation in the Journal of Clinical Oncology: Past, Present, and Future. 25:614-616. 2007
Meta-Analysis of Randomized Controlled Trials of Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor After Autologous and Allogeneic Stem Cell Transplantation. 24:5207-5215. 2006
Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. 24:4699-4707. 2006
In Reply. 24:4038a-4039. 2006
Phase II Trial of Preoperative Chemoradiation in Patients With Localized Gastric Adenocarcinoma (RTOG 9904): Quality of Combined Modality Therapy and Pathologic Response. 24:3953-3958. 2006
Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17. 24:3629-3635. 2006
Health Status Measurements at Diagnosis As Predictors of Survival Among Adults With Brain Tumors. 24:3636-3643. 2006
In Reply. 24:3711-3712. 2006
A comparison of BRCA1 and BRCA2 risk assessment models. 24:10034-10034. 2006
A comparison of patient and physician attributes that promote patient involvement in treatment decision making in the oncology consultation. 24:6098-6098. 2006
A phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) TheraCIM-h-R3 (nimotuzumab) in patients with advanced solid tumors. 24:13054-13054. 2006
A phase II trial of oblimersen sodium (G3139) in combination with doxorubicin (DOX) in advanced hepatocellular carcinoma (HCC). NCI protocol # 5798. 24:14072-14072. 2006
A randomized controlled trial (RCT) of long-term follow-up for early stage breast cancer comparing family physician to specialist care: A report of secondary outcomes. 24:6003-6003. 2006
A randomized controlled trial to evaluate the impact of an educational DVD on cancer patients considering participation in a phase I clinical trial. 24:6011-6011. 2006
Agreement between physicians and patients about what constitutes shared decision making. 24:6065-6065. 2006
Angiogenesis pathway gene polymorphisms associated with clinical outcome in recurrent ovarian cancer treated with low dose cyclophosphamide and bevacizumab: A California Consortium Trial. 24:5017-5017. 2006
Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study. 24:4516-4516. 2006
Bortezomib is active in Waldenstrom’s Macroglobulinemia (WM)—Results of a National Cancer Institute of Canada (NCIC) phase II study in previously untreated or treated WM. 24:7543-7543. 2006
Cognitive impairment associated with chemotherapy for breast cancer: An exploratory case-control study. 24:8501-8501. 2006
Cytokine levels in patients (pts) with localized colorectal cancer (CRC) after surgery and their relationship to fatigue and cognitive function. 24:3623-3623. 2006
Delays in diagnosis and initiating treatment for patients with lung cancer. 24:6102-6102. 2006
Diagnostic assessment of suspected cancer: Prospective cohort study of diagnostic delay intervals across three disease sites. 24:6029-6029. 2006
Direct decompressive surgery with post-operative radiotherapy (S + RT) versus radiotherapy (RT) alone for the treatment of metastatic epidural spinal cord compression (MESCC): A cost-utility analysis using Ontario health economic data. 24:8570-8570. 2006
Dose banding of chemotherapy doses at the Juravinski Cancer Centre. 24:6099-6099. 2006
Effects of adjuvant chemotherapy on the protein C anticoagulant pathway in patients with early stage breast cancer. 24:8563-8563. 2006
Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C) + paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): A study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). 24:3054-3054. 2006
Left ventricular function following adjuvant chemotherapy for breast cancer: The NCIC CTG MA5 experience. 24:522-522. 2006
Long-term results of concurrent gemcitabine (G) and radiotherapy (GRT) for locally advanced (LA) or high-risk resected (R) pancreatic cancer. 24:4101-4101. 2006
NCIC CTG MA.17: Tolerability of letrozole among ethnic minority women. 24:6018-6018. 2006
Neuroendocrine tumors (NET) of the gastrointestinal tract: A decade of experience at the Princess Margaret Hospital. 24:4093-4093. 2006
Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP). 24:4631-4631. 2006
Phase II study of sorafenib (BAY 43–9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial. 24:5084-5084. 2006
Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). 24:533-533. 2006
Quality of life (QOL) of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) following treatment with docetaxel or mitoxantrone in the TAX-327 study. 24:4557-4557. 2006
Understanding and preferences for receiving prognostic information: A comparison of the views of Australian and Canadian patients with metastatic cancer. 24:6014-6014. 2006
Understanding decision supports (DS) for women with breast cancer eligible for clinical trials (CT). 24:10534-10534. 2006
Who are the users of publicly reported cancer treatment wait times (WT)?. 24:6043-6043. 2006
Ten-Year Multi-Institutional Results of Breast-Conserving Surgery and Radiotherapy in BRCA1/2-Associated Stage I/II Breast Cancer. 24:2437-2443. 2006
Phase III Trial of an Emulsion Containing Trolamine for the Prevention of Radiation Dermatitis in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Trial 99-13. 24:2092-2097. 2006
In Utero Exposure to Chemotherapy: Effect on Cardiac and Neurologic Outcome. 24:e16-e17. 2006
Incidence, Risk Factors, and Outcomes of Catheter-Related Thrombosis in Adult Patients With Cancer. 24:1404-1408. 2006
Clinical and Molecular Studies of the Effect of Imatinib on Advanced Aggressive Fibromatosis (desmoid tumor). 24:1195-1203. 2006
Quality of Randomized Controlled Trials Reporting in the Primary Treatment of Brain Tumors. 24:1136-1144. 2006
Randomized Trial of Long-Term Follow-Up for Early-Stage Breast Cancer: A Comparison of Family Physician Versus Specialist Care. 24:848-855. 2006
The Importance of Reporting Patient Recruitment Details in Phase III Trials. 24:843-845. 2006
Overstated Conclusions of a Pooled Analysis of Bevacizumab in Colon Cancer. 24:528-529. 2006
In Reply:. 23:8915-8916. 2005
Trastuzumab Cardiac Side Effects: Only Time Will Tell. 23:7775-7776. 2005
Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women. 23:6931-6940. 2005
In Reply:. 23:7244-7244. 2005
In Reply:. 23:7250-7250. 2005
In Reply:. 23:6267-6267. 2005
In Reply:. 23:6273-6274. 2005
Incidence and Prognostic Impact of Amenorrhea During Adjuvant Therapy in High-Risk Premenopausal Breast Cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Study—NCIC CTG MA.5. 23:6002-6008. 2005
Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle. 23:6107-6116. 2005
Randomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate Cancer. 23:6132-6138. 2005
Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer. 23:5597-5604. 2005
Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. 23:5166-5170. 2005
Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkin’s Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. 23:4634-4642. 2005
Catheter-Associated Thrombosis: Thromboprophylaxis or Not?. 23:4006-4008. 2005
Randomized Placebo-Controlled Study of Low-Dose Warfarin for the Prevention of Central Venous Catheter–Associated Thrombosis in Patients With Cancer. 23:4063-4069. 2005
A phase II study of BAY 43–9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC). 23:5566-5566. 2005
A phase II study of UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A Princess Margaret Phase II Consortium Trial. 23:3127-3127. 2005
A phase II study of triapine in combination with gemcitabine in advanced pancreatic carcinoma: A Princess Margaret Hospital Phase II Consortium Trial. 23:4093-4093. 2005
A phase II trial of perifosine as second line therapy for advanced pancreatic cancer. A study of the Princess Margaret Hospital [PMH] Phase II Consortium. 23:4166-4166. 2005
A phase II trial of preoperative chemotherapy and chemoradiotherapy for potentially resectable adenocarcinoma of the stomach (RTOG 99–04). 23:4019-4019. 2005
A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas (NECs). 23:3096-3096. 2005
A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell Lung cancer (NSCLC) (NCI T99–0046, RTOG 02–70, MDA 99–303): An interim report of toxicity and response. 23:7144-7144. 2005
Analysis of Treatment Practices for Elderly Cancer Patients in Ontario, Canada. 23:3802-3810. 2005
Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta analysis of the literature. 23:6082-6082. 2005
Determinants of preferences for starting extended adjuvant letrozole (L) in postmenopausal women following five years of tamoxifen. 23:642-642. 2005
Evaluation of responsiveness to change to psychosocial group therapy (PGT) and to the process of dying of psychosocial and quality of life (QOL) measures. 23:8035-8035. 2005
Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial. 23:5000-5000. 2005
Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors. 23:7253-7253. 2005
Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital [PMH] Phase II Consortium. 23:4677-4677. 2005
Predictive value of eTag dimerization assay in patients with metastatic colorectal cancer treated with erlotinib. 23:9618-9618. 2005
Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC). 23:LBA7004-LBA7004. 2005
S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results. 23:LBA7012-LBA7012. 2005
The impact and perception of mandatory tumor biopsies (Bx) for correlative studies in clinical trials of novel anticancer agents. 23:6006-6006. 2005
What are the supportive care service needs of recently diagnosed cancer patients? Results of a population based study. 23:8096-8096. 2005
Willingness of older people with cancer to participate in cancer clinical trials is not a barrier to accrual. 23:8245-8245. 2005
In Reply:. 23:3633-3634. 2005
Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. 23:2831-2839. 2005
Randomized Comparison of Low Molecular Weight Heparin and Coumarin Derivatives on the Survival of Patients With Cancer and Venous Thromboembolism. 23:2123-2129. 2005
Physician/Patient Decision Aids for Adjuvant Therapy. 23:1627-1630. 2005
Preface to Special Edition on Breast Cancer. 23:1595-1595. 2005
Use of Conventional Radiation Therapy As Part of Breast-Conserving Treatment. 23:1718-1725. 2005
The Metrics of Clinical Trials. 23:1589-1590. 2005
Communicating With Realism and Hope: Incurable Cancer Patients' Views on the Disclosure of Prognosis. 23:1278-1288. 2005
Randomized Trial Comparing Iridium Implant Plus External-Beam Radiation Therapy With External-Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate. 23:1192-1199. 2005
Influence of Sex on Toxicity and Treatment Outcome in Small-Cell Lung Cancer. 23:850-856. 2005
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004. 23:619-629. 2005
American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. 23:619-629. 2005
Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study. 23:585-590. 2005
Radiation Therapy and Tamoxifen: Concurrent or Sequential? That Is the Question. 23:1-4. 2005
Role of Lung Transplantation in the Treatment of Bronchogenic Carcinomas for Patients With End-Stage Pulmonary Disease. 22:4351-4356. 2004
Health-Related Quality of Life and Psychosocial Status in Breast Cancer Prognosis: Analysis of Multiple Variables. 22:4184-4192. 2004
Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Decrease Febrile Neutropenia After Chemotherapy in Children With Cancer: A Meta-Analysis of Randomized Controlled Trials. 22:3350-3356. 2004
A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy. 22:5054-5054. 2004
A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy. 22:5054-5054. 2004
A randomized controlled trial (RCT) of routine follow-up for early stage breast cancer: A comparison of primary care versus specialist care. 22:665-665. 2004
A randomized controlled trial (RCT) of routine follow-up for early stage breast cancer: A comparison of primary care versus specialist care. 22:665-665. 2004
Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen. 22:517-517. 2004
Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen. 22:517-517. 2004
Cancer patients and the Internet: A randomized controlled trial (RCT) evaluating an intervention to facilitate physician and patient information exchange from the Internet (I). 22:6139-6139. 2004
Cancer patients and the Internet: A randomized controlled trial (RCT) evaluating an intervention to facilitate physician and patient information exchange from the Internet (I). 22:6139-6139. 2004
Characteristics of out-of-pocket costs for cancer patients in Ontario, Canada. 22:8251-8251. 2004
Characteristics of out-of-pocket costs for cancer patients in Ontario, Canada. 22:8251-8251. 2004
Chemo-radiotherapy versus radiotherapy alone for nasopharyngeal carcinoma: A meta-analysis of 78 randomized controlled trials (RCTs) from English and non-English databases. 22:5522-5522. 2004
Chemo-radiotherapy versus radiotherapy alone for nasopharyngeal carcinoma: A meta-analysis of 78 randomized controlled trials (RCTs) from English and non-English databases. 22:5522-5522. 2004
Comparison of outcomes of phase II trials (P2Ts) and subsequent randomized control trials (RCTs) using identical therapeutic regimens. 22:6000-6000. 2004
Comparison of outcomes of phase II trials (P2Ts) and subsequent randomized control trials (RCTs) using identical therapeutic regimens. 22:6000-6000. 2004
Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: A National Cancer Institute Of Canada Clinical Trials Group Study: MY.7. 22:6510-6510. 2004
Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: A National Cancer Institute Of Canada Clinical Trials Group Study: MY.7. 22:6510-6510. 2004
Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. 22:5005-5005. 2004
Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. 22:5005-5005. 2004
Patterns of trastuzumab (T) use in three Canadian provinces. 22:633-633. 2004
Patterns of trastuzumab (T) use in three Canadian provinces. 22:633-633. 2004
Practitioner feedback on clinical practice guidelines developed by Cancer Care Ontario's Lung Disease Site Group: Extending the circle of involvement. 22:6031-6031. 2004
Practitioner feedback on clinical practice guidelines developed by Cancer Care Ontario's Lung Disease Site Group: Extending the circle of involvement. 22:6031-6031. 2004
Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR.18. 22:7038-7038. 2004
Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR.18. 22:7038-7038. 2004
Retrospective analysis of treatment practices for elderly cancer patients (Pts) in Ontario, Canada. 22:8168-8168. 2004
Retrospective analysis of treatment practices for elderly cancer patients (Pts) in Ontario, Canada. 22:8168-8168. 2004
Supportive care in cancer. Who does what?. 22:8267-8267. 2004
Supportive care in cancer. Who does what?. 22:8267-8267. 2004
Thromboembolism (TE) in children with acute lymphoblastic leukemia (ALL) treated on Dana Farber Cancer Institute (DFCI) protocols: Effect of dose and type (prednisone versus dexamethasone) of steroids used. 22:8525-8525. 2004
Thromboembolism (TE) in children with acute lymphoblastic leukemia (ALL) treated on Dana Farber Cancer Institute (DFCI) protocols: Effect of dose and type (prednisone versus dexamethasone) of steroids used. 22:8525-8525. 2004
Tolerability of the Intergroup 0099 regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. 22:5572-5572. 2004
Tolerability of the Intergroup 0099 regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. 22:5572-5572. 2004
Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. 22:2328-2335. 2004
Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS). 22:1944-1948. 2004
Cancer Patient Preferences for Communication of Prognosis in the Metastatic Setting. 22:1721-1730. 2004
Skeletal Morbidity in Childhood Acute Lymphoblastic Leukemia. 22:1215-1221. 2004
Evaluation of Diagnostic Assessment Units in Oncology: A Systematic Review. 22:1126-1135. 2004
Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression. 22:1063-1070. 2004
Economics of Preoperative Radiotherapy With Total Mesorectal Excision: What Can We Learn From the Dutch Experience?. 22:217-219. 2004
Researching the Cost of Research. 21:4081-4082. 2003
Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel. 21:3965-3971. 2003
Risk of Acute Leukemia Following Epirubicin-Based Adjuvant Chemotherapy: A Report From the National Cancer Institute of Canada Clinical Trials Group. 21:3066-3071. 2003
Height and Weight in Children Treated for Acute Lymphoblastic Leukemia: Relationship to CNS Treatment. 21:2953-2960. 2003
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma. 21:2636-2644. 2003
American Society of Clinical Oncology Technology Assessment Working Group Update: Use of Aromatase Inhibitors in the Adjuvant Setting. 21:2597-2599. 2003
Phase II Study of the Efficacy and Tolerability of Two Dosing Regimens of the Farnesyl Transferase Inhibitor, R115777, in Advanced Breast Cancer. 21:2492-2499. 2003
Quality of Life in a Randomized Trial of Group Psychosocial Support in Metastatic Breast Cancer: Overall Effects of the Intervention and an Exploration of Missing Data. 21:1944-1951. 2003
CORRESPONDENCE. 21:1895-1895. 2003
Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group. 21:1740-1745. 2003
Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B₁₂ as Front-Line Therapy in Malignant Pleural Mesothelioma. 21:1556-1561. 2003
Shared Treatment Decision Making: What Does It Mean to Physicians?. 21:932-936. 2003
Application of Breast Cancer Risk Prediction Models in Clinical Practice. 21:593-601. 2003
neu/erbB-2 Overexpression and Response to Hormonal Therapy in Premenopausal Women in the Adjuvant Breast Cancer Setting: Will It Play in Peoria? Part II. 21:399-400. 2003
Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy.. 21:35-40. 2003
Randomized Phase III Study of Fludarabine Phosphate Versus Cyclophosphamide, Vincristine, and Prednisone in Patients With Recurrent Low-Grade Non-Hodgkin’s Lymphoma Previously Treated With an Alkylating Agent or Alkylator-Containing Regimen. 20:4649-4654. 2002
A Trial of Two Questions. 20:4135-4138. 2002
Do Quality-of-Life Randomized Clinical Trials Support Clinicians in Their Decision-Making?. 20:4126-4127. 2002
Do quality-of-life randomized clinical trials support clinicians in their decision-making? Reply. 20:4127-4127. 2002
Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma. 20:3533-3544. 2002
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor–Positive Breast Cancer: Status Report 2002. 20:3317-3327. 2002
Beyond the Development of Quality-of-Life Instruments: Where Do We Go From Here?. 20:2215-2216. 2002
Breast Cancer Consensus Meetings: Vive la Difference?. 20:1719-1920. 2002
Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.. 20:1677-1682. 2002
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.. 20:1167-1174. 2002
Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix.. 20:966-972. 2002
Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed. 20:205-213. 2002
Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed. 20:205-213. 2002
Phase I Study of Combination Topotecan and Carboplatin in Pediatric Solid Tumors. 20:88-95. 2002
Phase I Study of Combination Topotecan and Carboplatin in Pediatric Solid Tumors. 20:88-95. 2002
Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01.. 20:237-246. 2002
Randomized Clinical Trials in Oncology: Understanding and Attitudes Predict Willingness to Participate. 19:3554-3561. 2001
Funding New Cancer Drugs in Ontario: Closing the Loop in the Practice Guidelines Development Cycle. 19:3392-3396. 2001
Strategies to Manage the Adverse Effects of Oral Morphine: An Evidence-Based Report. 19:2542-2554. 2001
Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*. 19:1539-1569. 2001
Anthracycline Adjuvant Chemotherapy: How Much Is Enough?. 19:599-601. 2001
Structured Exercise Improves Physical Functioning in Women With Stages I and II Breast Cancer: Results of a Randomized Controlled Trial. 19:657-665. 2001
Bleomycin-Induced Lung Toxicity and Pentoxifylline. 19:597-598. 2001
Prophylactic surgery: Oophorectomy or adnexectomy? Reply. 18:3455-3455. 2000
Health-Related Quality of Life in Survivors of Wilms’ Tumor and Advanced Neuroblastoma: A Cross-Sectional Study. 18:3280-3287. 2000
Does Locoregional Radiation Therapy Improve Survival in Breast Cancer? A Meta-Analysis. 18:1220-1229. 2000
Phase II Trial of N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and Doxorubicin Chemotherapy in Metastatic Breast Cancer: A National Cancer Institute of Canada Clinical Trials Group Study. 17:3431-3437. 1999
Health-Related Quality of Life in Men With Metastatic Prostate Cancer Treated With Prednisone Alone or Mitoxantrone and Prednisone. 17:1654-1654. 1999
Mastectomy or Lumpectomy? Helping Women Make Informed Choices. 17:1727-1727. 1999
Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study. 17:1194-1194. 1999
Costs of Treating and Preventing Nausea and Vomiting in Patients Receiving Chemotherapy. 17:344-344. 1999
Adjuvant chemotherapy with CEF versus CMF for node-positive breast cancer.. 16:3916-3917. 1998
Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study.. 16:3524-3527. 1998
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. 16:2651-2658. 1998
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.. 16:2651-2658. 1998
Ethics of randomized clinical trials.. 16:2570. 1998
Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points.. 16:2272-2279. 1998
Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback.. 16:1226-1231. 1998
Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. 16:1174-1178. 1998
Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.. 16:1174-1178. 1998
Combined modality therapy for lung cancer - Reply. 16:808-808. 1998
Combined modality therapy for lung cancer.. 16:807-808. 1998
Cost of combined modality interventions for stage III non-small-cell lung cancer.. 15:3038-3048. 1997
Lung cancer practice guidelines: lessons learned and issues addressed by the Ontario Lung Cancer Disease Site Group.. 15:3049-3059. 1997
Treatment of Advanced Hodgkin's Disease With Chemotherapy—Comparison of MOPP/ABV Hybrid Regimen With Alternating Courses of MOPP and ABVD. 15:2762-2762. 1997
Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.. 15:2302-2311. 1997
Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease.. 15:2322-2328. 1997
Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin.. 15:1897-1905. 1997
Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.. 15:1638-1645. 1997
Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective.. 15:632-639. 1997
Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. 14:2083-2090. 1996
Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.. 14:2083-2090. 1996
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.. 14:1756-1764. 1996
Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology.. 14:1957-1960. 1996
Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy.. 14:1413-1420. 1996
Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant.. 14:1327-1332. 1996
Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology.. 14:671-679. 1996
Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma.. 13:2386-2393. 1995
Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.. 13:2354-2360. 1995
Breast irradiation postlumpectomy: development and evaluation of a decision instrument.. 13:847-853. 1995
The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation.. 13:502-512. 1995
Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation.. 13:42-46. 1995
Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer.. 12:2648-2653. 1994
Therapy-related leukemia associated with high-dose 4-epi-doxorubicin and cyclophosphamide used as adjuvant chemotherapy for breast cancer.. 12:2514-2515. 1994
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.. 12:689-694. 1994
Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?. 11:1866-1872. 1993
Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group.. 11:1592-1597. 1993
The physician as the patient's advocate. American Society of Clinical Oncology Committee of Patient Advocacy.. 11:1011-1013. 1993
The Head and Neck Radiotherapy Questionnaire: a morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer.. 11:863-872. 1993
Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.. 11:336-344. 1993
Second primary malignancies following diagnosis of small-cell lung cancer.. 10:1525-1533. 1992
The HER-2/neu oncogene in breast cancer: so what is new?. 10:1034-1036. 1992
A comprehensive multiattribute system for classifying the health status of survivors of childhood cancer.. 10:923-928. 1992
Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer.. 10:297-303. 1992
Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer.. 10:21-27. 1992
Combined modality therapy of Hodgkin's disease: 10-year results of National Cancer Institute of Canada Clinical Trials Group multicenter clinical trial.. 9:1983-1993. 1991
Small-cell carcinoma of the lung: derivation of a prognostic staging system.. 9:1639-1649. 1991
Dose intensity and lymphoma.. 9:1511-1511. 1991
The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer.. 9:954-961. 1991
Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group.. 9:729-735. 1991
The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma.. 9:339-347. 1991
When is a prognostic factor useful? A guide for the perplexed.. 9:348-356. 1991
A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer.. 8:1217-1225. 1990
Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer.. 8:390-395. 1990
Late neurological complications after prophylactic cranial irradiation in patients with small-cell lung cancer: the Toronto experience.. 8:215-221. 1990
Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial.. 8:203-208. 1990
Thromboembolic risk of tamoxifen in patients with stage II breast cancer.. 7:1579-1580. 1989
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.. 7:1157-1168. 1989
Quality of life in stage II breast cancer: an instrument for clinical trials.. 6:1798-1810. 1988
Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer.. 6:1537-1547. 1988
Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report.. 6:1254-1263. 1988
Methotrexate/fluorouracil scheduling influences normal tissue toxicity but not antitumor effects in patients with squamous cell head and neck cancer: results from a randomized trial.. 6:963-968. 1988
Adjuvant chemotherapy following surgical resection for small-cell carcinoma of the lung.. 6:832-838. 1988
Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.. 6:633-641. 1988
Chemotherapy following surgery for stages IE and IIE non-Hodgkin's lymphoma of the gastrointestinal tract.. 6:253-260. 1988
Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.. 5:1401-1409. 1987
Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma.. 5:635-640. 1987
A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer.. 5:113-124. 1987
High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study.. 5:75-82. 1987
Bench-to-bedside research and the human tumor stem-cell assay--bridging the credibility gap.. 4:1730-1731. 1986
DOSE INTENSITY AND RESPONSE - REPLY. 4:1865-1865. 1986
Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer.. 4:1162-1170. 1986
Tetracycline sclerosis in the management of malignant pericardial effusion.. 3:1678-1682. 1985
Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer.. 3:1478-1485. 1985
Treatment of pathologic stages IA and IIA Hodgkin's disease.. 3:1563-1564. 1985
VP-16 and cisplatin as first-line therapy for small-cell lung cancer.. 3:1471-1477. 1985
Carcinoembryonic antigen: a useful prognostic marker in small-cell lung cancer.. 3:1349-1354. 1985
Effects of intravenous hyperalimentation during treatment in patients with small-cell lung cancer.. 3:949-957. 1985
CORRECTION. 3:1045-1045. 1985
Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer.. 3:65-71. 1985
Methodologic issues in trials of antiemetics.. 2:484-487. 1984
Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung.. 2:294-304. 1984
Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer.. 1:787-792. 1983
Intramedullary spinal cord metastases from small cell carcinoma of the lung.. 1:99-106. 1983

Journal of Clinical Oncology Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)